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Chapter 1 
SCOPE OF THIS THESIS 
Androgens exert their action after binding to cyto-
plasmic receptors resulting in the formation of androgen-
receptor complexes. This initial event is followed by acti-
vation, translocation to the nucleus and interaction with 
chromatin acceptor sites of the androgen-receptor comulexes. 
Bound to chromatin, the androgen-receptor complex stimulates 
many biochemical events resulting in gene expression and 
starting with RNA-synthesis. Further detailed understanding 
of the complex processes requires a purified receptor prepa-
ration. Due to the low amount of receptors present ln andro-
gen target organs, large scale isolation of these receptors 
requires a suitable source. Thusfar it seems that androgen 
receptors from different sources have similar characteris-
tics. In this respect seminal vesicles of the ram contain 
an androgen receptor comparable to the receptor present in 
rat prostate (chapter 4.3 and appendix paper II). Studies 
were performed to purify the receptor present ln ram seminal 
vesicles, and an almost two thousand fold purified receptor 
preparation has been obtained (chapter 4.4 and appendix 
paper III). Nuclear localization and acceptor sites of 
androgen-receptor complexes on the chromatin in target cells 
have hardly been studied. To gain more insight in the mecha-
nism of interaction of androgen-receptor complexes with 
chromatin acceptor sites, the usefulness of purified andro-
gen receptors was investigated. In preliminary studies high 
affinity interaction of androgen-receptor complexes with 
isolated chromatin was observed (chapter 5) and the possibi-
lities for further investigation are discussed (chapters 6.3 
and 6.4). 
There is now ample evidence that human breast cancer 
can be treated with more success with endocrine therapy if 
the tumor tissue contains specific receptor proteins for the 
steroid hormone estradiol. For human prostatic cancer which 
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can be influenced by androgens, it is still not known 
whether a correlation exists between androgen receptor con-
tent and the response to endocrine treatment. A reliable an-
drogen receptor assay is 
of cytoplasmic receptors 
ciated with many problems 
therefore a necessity. Measurement 
in human prostatic tissue is asso-
(chapter 3.1.2). In addition, con-
troversial results have been reported in the literature con-
cerning the relationship between cytoplasmic androgen recep-
tor content and the benefit from endocrine management of 
prostatic diseases. For this reason, a nuclear receptor 
assay was developed for human prostatic tissue (chapter 3.2 
and appendix paper I). This method can be applied to the 
evalution of a possible correlation between receptor content 
of prostatic tumors and clinical response to endocrine 
therapy. 
Chapter 2 
GENERAL INTRODUCTION ON THE MECHANISM OF ACTION OF STEROIDS 
This chapter describes the known and unknown biochemical 
processes which can play a role 1n the effects of steroid 
hormones. 
Steroid receptors are intracellular proteins which 
interact with steroids through specific binding sites to 
form hormone-receptor complexes. Once the steroid-receptor 
complex has been formed an integrated sequence of molecular 
events is started (figure 2.1). Such steroid receptors are 
characterized by steroid specificity, target cell specifi-
city, high affinity for their specific steroids and low con-
centration (Gorski et al., 1968; Baulieu et al., 1971). 
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Figure 2.1: Simplified scheme for the action of steroids on 
their target cells. 
Free steroids (S) enter the cell and bind to the cytoplasmic 
receptor (Rc) to form a steroid-receptor complex (SRc). Activa-
tion of SRc results in SRcact which migrates to the nucleus 
(SRn). The nuclear receptor (SRn, probably identical to SRcact) 
interacts with the chromatin which ultimately results in the 
hormonal effects. 
Steroids can interact with different proteins in 
blood. This binding has been reviewed in detail by Westphal 
(1971, 1978). The affinity of these proteins for steroids 
varies from very low to very high and they are frequently 
present in high concentrations. Serum albumin, present ~n 
large amounts in vascular and extracellular spaces, has a 
relatively low affinity for several steroids, such as tes-
tosterone, estradiol and progesterone. More specific steroid 
binding proteins, which are present in smaller amounts (less 
than 1%), have higher affinities for their specific steroid 
hormones. Sex Hormone Binding Globulin ( SHBG), present ~n 
man, binds 
stants of 
testosterone 
1.2 and 0.5 
and 
X 
estradiol 
10 9 M-l, 
with affinity con-
respectively. Other 
steroid binding proteins, such as Corticosteroid Binding 
Protein (CBG) and Progesterone Binding Protein (PBG), bind 
their steroids with affinities of the same order of 
magnitude. 
Steroids are biologically inactive as long as they are 
associated with serum proteins (Westphal, 1978; Rao, 1981). 
The amount of these steroid binders may change with changing 
levels of hormones. Because binding proteins can influence 
the amount of free hormone available for receptor binding 
inside the cell, they can be important in the control of 
steroid hormone action. 
mones 
One of the least understood 
is their mode of entry into 
aspects of steroid 
target cells. Early 
hor-
stu-
dies of steroid uptake have involved ~n v~vo or in vitro 
exposure of target and non-target tissues to labelled ste-
roid (Jensen & Jacobson, 1962; Gorski et al., 1968). Such 
studies indicated that a saturable component is involved ~n 
steroid uptake, and might reflect the retention of steroid 
after interaction with binding proteins inside the cell, 
rather than a limited rate of entry. The suggestion that es-
trogens partition between the blood and the tissue in a non-
specific, passive manner, has also been reported (Peck et 
al., 1973). The precise mode of entry of steroids into 
target cells is still unknown and conflicting results have 
been described as reviewed by King & Mainwaring (1974), 
Mainwaring 0977) and Rao (1981). Most results support the 
idea that steroid uptake occurs by passive diffusion 
(Muller et al., 1979). This might also be expected because 
of the lipophilic properties of steroids, which facilitate 
easy permeation of steroids through the plasma membrane 
which is rich in lipids. 
Following their entry into target cells, steroids may 
both bind to var~ous high capacity low affinity binding 
sites within the cytoplasmic compartment and to the cyto-
plasmic receptor for that specific steroid to form a 
steroid-receptor complex. Specific receptors, which are 
present ~n limited amounts, have been found for each of 
five physiologically well-defined steroid hormones: estrogen 
receptors, early described ~n rat uterus (Jensen & Jacobson, 
1962); androgen receptors in rat ventral prostate (Fang et 
al., 1969; Mainwaring, 1969); progesterone receptors ~n 
guinea pig uterus (Milgram et al., 1970) and ~n chick ov~­
duct (O'Malley et al., 1970); glucocorticoid receptors ~n 
thymus cells (Munck & Wira, 1971) and mineralocorticoid re-
ceptor in toad bladder (Sharp et al., 1966) and also studied 
in rat kidney (Swaneck et al., l970L Specific steroid-
17 
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receptor interaction is characterized by a high affinity 
(Ka: 10 9 10lO M-1). The receptors are present ln low 
amounts (values varying between and 
molecules per cell) 
Cytoplasmic steroid receptors, isolated ln hypotonic 
media from a variety of tissues, sediment on sucrose gra-
dients as an 7-9 S entity, as described ln early reports 
for estrogen 
Rochefort & 
recepto>s 
Baulieu, 
(Milgram et al., 1970; 
(Toft & 
1968), 
Gorski, 1966; Erdos, 1968; 
for progesterone receptors 
Sherman et a 1., 1970; McGuire & 
DeDella, 
Tomkins, 
1971), 
1971 
for glucocorticoid 
Beato & Feigelson, 
receptors 
1972) and 
(Baxter & 
for mlne-
ralocorticoid receptors (Herman et al., 1968). All these cy-
toplasmic steroid receptors dissociate into smaller compo-
nents at high salt concentrations (0.4 M KCl). 
For the cytoplasmic androgen receptors, isolated ln 
hypotonic media from rat prostate, sedimention coefficients 
between 7 S and 12 S have been reported, as reviewed by 
Hiipakka et al. (1980). These large forms can be transformed 
to the slower sedimenting 3-5 S forms by incubations at 
20-30°C or by raising the salt concentration to 0.4 M 
KCl (Baulieu et al., 1971). Under some conditions the smal-
ler forms can also be converted to larger forms (Liao et 
al., 1975; Hu & Wang, 1978; Colvard & Wilson, 1981). How-
ever, aggregation as well as the formation of the 8 S form, 
which can be provoked by changes in pH (Liao et al., 1975), 
do not occur with partially purified androgen-receptor com-
plexes (Liao & Liang, 1974). Liao and associates, therefore, 
suggested that the formation of the 8 S form obviously in-
volves other cellular materials (Tymoczko et al., 1978). 
This suggestion was also made by Colvard & Wilson (1981) who 
postulated an "8 S androgen receptor-promoting factor" which 
converts the 4. 5 S form of the receptor to the 8 S form. 
This factor, present in serum of mature male rats and in all 
tissues of male rats known to contain androgen receptors, 
appeared to be produced by androgen responsive cells. 
Whether the large differences ln receptor size, as 
discussed above, simply reflect preparative methods lS not 
clear. In this respect, studies of Wilson & French (1979) 
using the protease inhibitor diisopro~yl fluorophosphate 
( D F P ) and other pro tea s e i nh i b i tors , s u g g e s t that receptor 
degradation leading to the 3.6 S and 3.0 S forms ~s an in 
vitro phenomenon as a result of proteolytic degradation. 
Recently in our laboratory, only a small increase in sedi-
mentation coefficient of rat 
(3.0 to 3.5 S) has been observed 
prostate androgen receptor 
after homogenization of the 
tissue in the presence of DFP (Mulder et al., 1981). It was 
shown that also several other substances, e.g., pyridoxal 
5 '-phosphate, heparin and Cibacron blue effect the sedimen-
tation coefficient. 
Apart from the commonly studied sedimentation beha-
viour, several other criteria have been used for the charac-
terization of steroid receptors. For androgen receptors, the 
8 S form appears to have a molecular weight 
Einstein-Stokes radius of 84 ~' a frictional 
of 276,000, 
ratio (f/fo) 
an 
of 
l. 96 and it requires SH-groups 
1969). The dissociation constant 
tosterone-receptor complex is 
for stability (Mainwaring, 
(Kd) of the 5a-dihydrotes-
-9 2.4-4.0 x 10 M (Ritzen 
et al., 1971; Mainwaring, 1977) and it has an isoe1ectric 
point (pi) of 5.8 (Mainwaring & Irving, 1973; Tindall et 
al., 1975). The receptor is extremely heat labile (Baulieu 
& Jung, 1970) and has a high affinity only for androgenic 
steroids (King & Mainwaring, 1974). 
translocation to the nucleus 
After binding of the steroid to cytoplasmic receptors 
several not completely understood processes occur before the 
steroid-receptor complex trans locates to the nucleus. The 
steroid-receptor complex rapidly changes its properties and 
is a term that ~n 
is 
some way becomes 
generally used to 
activated. 
define the 
"Activation" 
process whereby steroid re-
ceptors are converted to a form that can bind to either nu-
clei, chromatin, DNA or DNA-like substances. Experiments 
19 
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under cell-free conditions were initiated by Jensen and 
coworkers (Jensen et al., 1969; 1972) and they have shown 
after incubation that estrogen receptors in uterine cytosol, 
at low temperatures for short times with 
unable to bind to nuclei at 0°C, whereas 
were estradiol, 
the same estra-
25-300C dial-receptor 
would bind to 
complexes 
nuclei at 
temporarily 
0° C. This 
heated to 
activation process is 
associated with a shift in the dissociation rate constant of 
exponential 
been demon-
the steroid from its receptor. A two-component 
dissociation of estradiol from the receptor has 
strated (Weichman & Notides, 1977). The first, rapid estra-
the non-acti-dio1 dissociating component is a property of 
vated receptor, while the second, slower dissociating compo-
nent is a property of the activated receptor. Parallel to 
this activation, heating of the estradiol-receptor complexes 
also caused a change in their sedimentation from 4 S to 5 S 
on sucrose gradients at high ionic strength (Notides et al., 
1975). This change in receptor sedimentation coefficient is 
defined as receptor "transformation" (Bailley et al., 1980) 
and this shift to a faster sedimenting form has been obser-
ved only for ~stradiol-receptor complexes. The molecular 
details of receptor activation and transformation are not 
completely understood, but the conversion of the "native" 
4 S estradiol-receptor complex to the nuclear 5 S form 
appears to involve more than a simple conformational change. 
The activated or transformed complex (MW: 130,000-140,000) 
has a higher molecular weight than the native form (MW: 
70,000-80,000) (Yamamoto & Alberts, 1972; Little et a1., 
1973; Notides & Nielsen, 1974) and the conversion reaction 
follows second order kinetics (Notides et al., 1975; Little 
et al., 1975; Notides, 
5 S sedimenting from 
197 8). 
1978). It has been suggested that the 
1s a result of dimerization (Notides, 
Apart from heating, steroid receptor activation (defi-
ned as binding to DNA-cellulose or nuclei) can also be pro-
voked by other procedures, like: increasing ionic strength 
(Jensen & DeSombre, 1972; Mainwaring & Irving, 1973), ammo-
filum sulphate precipitation and gel filtration on sephadex 
G-25 (Liao et al., 1980), dilution (Bailley et al., 1977) or 
dialysis against buffer (Sato et a1., 1980). 
In contrast to estrogen receptors, activation and/or 
transformation of the dihydrotestosterone-receptor complex 
~s associated with a decrease in sedimentation rate to 3 S 
(Liao et al., 1975; this thesis: chapter 4.3). Similar de-
creases have been reported for the progesterone-receptor 
complexes of hamster (Chen & Leavitt, 1979) as well as 
guinea pig and rabbit uterus (Saffran et al., 1976) while no 
difference was observed in the sedimentation rates of native 
and activated progesterone-receptor complexes of chick ov~­
duct (Buller et al., 1975a) and for glucocorticoid-re-
ceptor complexes of rat liver (Kalimi et al., 1975). 
Much of the available information is ~n support of conside-
ring activa.tion as a temperature or salt induced conforma-
tional change in receptor molecules, but there ~s also evi-
dence that activation may be an enzymatic process. Fuca and 
coworkers have isolated and partially characterized from 
calf uterine cytosol a calcium-dependent protease, named 
"Receptor Transforming Factor", which converts the cytoplas-
mic estrogen receptor to a nuclear binding form (Fuca et 
al., 1972; Sica et al., 1973). The biological significance 
of these studies, however, remains to be established. Also 
~n human uterine cytosol a protein has been described, which 
~s different from the calf uterine "Receptor Transforming 
Factor" and which may also be involved ~n estrogen receptor 
activation (Notides et al., 1973). In addition it has been 
shown that exogeneous and endogeneous proteases in vitro can 
cleave the rat hepatic glucocorticoid receptor in smaller 
components with a greater binding capacity for nuclei and 
DNA-cellulose (Wrange & Gustafsson, 1978). 
21 
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In addition to the possible enzyme regulated activation of 
steroid-receptors, the presence of a receptor "activator" 
protein in rat uterine cytosol (Thampan & Clark, 1981) as 
well as of a macromolecular "inhibitor" protein of glucocor-
ticoid receptor activation (Simons et al., 1976), have been 
reported. In rat prostate, protein factors have been des-
cribed to inhibit binding of the androgen-receptor complex 
to cell nuclei and chromatin (Fang & Liao, 1971; Shyr & 
Liao, 
weight 
1978). Apart from proteins, 
components (RNA) have been 
other high molecular 
shown to interfere in 
interaction of androgen-receptor complexes with DNA-like 
substances (Liao et al., 1980; Lin & Ohno, 1981). 
Irrespective of high 
possible involvement 
which can inhibit the 
molecular weight components, the 
of low molecular weight components, 
activation process of several steroid 
receptors, have been described (Cake et al., 1976; Bailly 
et al., 1977; Goidl et al., 1977; Sato et al., 1978, 1979, 
1980). The low molecular weight inhibitor of glucocorticoid 
receptor activation was defined as "modulator" by Litwack 
and associates (Cake et al., 1976; Sekula et al., 1981). In 
subsequent studies was shown that increased intracellular 
levels of pyridoxal 5"-phosphate produced antiglucocorticoid 
effects whereas a reduction in pyridoxal 5 '-phosphate con-
tent increased the sensitivity of hepatoma cells in culture 
to glucocorticoids (DiSorbo & Litwack, 1981). It has been 
concluded from these data that pyridoxal 5'-phosphate is an 
in vivo modulator of the glucocorticoid receptor. The inhi-
bitory role of pyridoxal 5'-phosphate :Ln the binding of 
several steroid receptors to nuclei and DNA has been repor-
ted also by other laboratories, e.g., for glucocorticoid 
receptor of rat liver (Kalimi & Love, 1980), for the avian 
progesterone receptor (Nishigori & Toft, 1979), for androgen 
receptor of rat prostate (Hiipakka & Liao, 1980; Mulder et 
al., 1980) and for the uterine estrogen receptor (Muldoon & 
Cidlowski, 1980; Miiller et al., 1980; Traish et al., 1980). 
Other low molecular weight factors, ATP and Ca++ 
can promote activation of steroid-receptor complexes 
(Sherman et al., 1974, 1978; Kalimi, 1980; Moudgil & 
Eessalu, 1980; Moudgil & John, 1980). 
Recently several studies have been reported on the effect of 
molybdate on receptor activation. It appeared that molyb-
date, known as a phosphatase inhibitor, blocks or inhibits 
the activation of several steroid receptors (Leach et al., 
1979; Nishigori & Toft, 1980; Shyamala & Leonard, 1980). The 
inhibition of activation by molybdate might suggest that a 
dephosphorylation step ~s involved in receptor activation. 
Other reports have shown, however, that molybdate protects 
steroid receptors against degradation (Leach et al., 1979; 
Gaubert et al., 1980; Chen et al., 1981; Miller et al., 
1981), which might imply that a phosphorylated receptor ~s 
more stabile or that some proteolytic enzyme is inactive in 
i t s ph o s ph or y 1 a t e d f o rm • Hen c e , a ph o s ph or y 1 a t i on- de ph o s -
phory1ation mechanism involving a phosphatase may effect 
stability and activation of steroid receptors. There lS no 
definitive information, however, as to whether molybdate 
acts directly on the steroid-r·eceptor molecule or whether 
its effect on receptors is indirect, due to its interaction 
with other components in the cytosol. 
Conclusions 
In conclusion, the precise nature of the activation process 
which transforms steroid receptors to its chromatin binding 
form is still not solved. It remains unclear whether some 
protein factor in the cytoplasm or some low molecular weight 
component or a phosphorylation-dephosphorylation process is 
involved in the activation of steroid receptors. In light of 
the possibility that dephosphorylation of receptors may 
23 
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occur prior to recycling of receptors from the nucleus to 
the cytoplasm, a hyphothetical scheme involving activation, 
translocation and recycling of receptors l.S presented 1.n 
chapter 2.2.6. 
Very little is known about the translocation of ste-
roid receptors and other proteins from the cytoplasm to the 
nucleus. From 
of receptors 
the effect 
(Buller et 
of temperature 
al., 1975a'b) 
on transport rates 
and from studies 
on binding of receptors to isolated nuclear envelopes (Conn 
et al., 1977) it is not clear whether a specific carrier 
mechanism exists. However, studies of the involvement of ATP 
and inhibitors of nuclear uptake (Lohman & Toft, 1975) sug-
gest the i nvo 1 vemen t of an energy- dependent or enzymatic 
step in the uptake of receptors by nuclei. The nuclear con-
centration of steroid receptors may also simply reflect the 
hydrophobic nature of the steroid-receptor complex (Williams 
& Gorski, 1974; Sheridan et al., 1979, 1981). Whatever the 
mechanism of translocation may be, 
roid hormones exert their primary 
transcription. After binding of 
it seems likely that ste-
effects at the level of 
the activated steroid-
receptor complexes to "acceptor-sites" on nuclear chromatin, 
activation of the transcription process at chromatin 
"effector-sites" induces the appearance of specific new RNA-
sequences. Early experiments have been performed with seve-
ral steroid hormone systems, including estrogens 
al., 1968; O'Malley et al., 1969; King & Gordon, 
gestins (O'Malley & McGuire, 1968; Schwartz et 
glucocorticoids (Kenny & Kull, 1963; Baxter et 
and androgens (Fang & Liao, 1971; Mainwaring 
1971). 
(Jensen et 
1972), pro-
al., 1976), 
al., 1972) 
& Pe terken, 
The sequence of events, which result in the alteration 
of gene expression elicited by the steroid hormone, has been 
extensively studied in the chick oviduct system and has been 
reviewed by Thrall et al. (1978). Within 1 min after injec-
tion, labelled hormone can be detected within target and 
non-target cells. In target cells, the steroid is bound to 
its receptor within 1-2 min and the steroid-receptor com-
p~exes are detected bound to chromatin within 2-4 min after 
injection of the steroid. Within 5 min of injection, the 
steroid in target cells is predominantly bound to the nu-
cleus whereas in non-target cells the steroid diffuses back 
into circulation. The synthesis of different gene product 
does not always occur as a primary event. For example, the 
egg-white protein, conalbumin, begins to acculmulate very 
soon after estrogen administration, while this occurs only 
after 3 h for ovalbumin (Palmiter et al., 1976). In a recent 
study (Palmiter et al., 1981) it has been suggested that a 
single binding site for the receptor is involved ~n con-
albumin gene regulation and multiple sites are involved ~n 
ovalbumin gene regulation. 
The amount of receptors necessary for full physiologi-
cal response is not precisely known. Total concentrations of 
cellular steroid receptors have been reported for many dif-
ferent tissues in many different species (King & Mainwaring, 
1974). A reasonable average amount for the total number of 
per uterine cell ~s approxima-
1979; Clark et al., 1980), where-
are involved ~n full uterotrophic 
estrogen receptor molucules 
tely 20,000 (Clark & Peck, 
as only 1,000-2,000 sites 
response (Clark & Peck, 1979). The remaining receptors, 
according to Clark, are present mainly to ensure that the 
steroid is effectively accumulated in the target cell. These 
findings are supported by Mulvihil & Palmiter (1980) who 
have shown that 800-1,500 nuclear acceptor sites per tubular 
gland cell of the chick oviduct must be occupied with pro-
gesterone-receptor complex for 8 h in order to get full 
induction of conalbumin mRNA and ovalbumin mRNA. 
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Nuclear DNA is organized into nucleosomes which consist of a 
core particle containing an octomer of histones H2A, H2B, H3 
and H4 (two each), surrounded by 140 nucleotide pairs of DNA 
(Felsenfeld, 1978), and an internucleosomal or linker region 
which is composed of about 60 nucleotide pairs of DNA and 
histon H1 (Kornberg, 1974; Noll, 1974). These nucleosomes 
are surrounded by non-histone proteins. The repeating sub-
unit structure of the chromatin is shown in figure 2.2. The 
mechanism of transfer of the biochemical information, con-
tained in steroid-receptor complexes, to the transcriptional 
apparatus is still a central problem in steroid hormone 
action. Many laboratories are involved in investigations on 
the precise nature and subnuclear distribution of the accep-
tor sites for the activated steroid-receptor complexes and 
nucleosome 
DNA DNA 
hi stones linker 
Figure 2.2: Repeating subunit structure of the chromatin. 
on the biochemical effects of this interaction for the regu-
lation of biochemical events, ~n particular 
Most of the steroid-receptor complexes are 
the chromatin (Spelsberg, 1974). In addition, 
isolated steroid-receptor complexes to the 
been shown to be a saturable process (Kon 
RNA synthesis. 
associated with 
the binding of 
chromatin has 
et al., 1980; 
Thrall & Spelsberg, 1980; Tsai et a1., 1980). Many compo-
nents of the nucleus have been proposed as the acceptor. 
Estradiol-receptor complexes have been found in association 
with, or have shown an affinity for respectively, histones 
(Ka1los et al., 1981), non-histones (Spe1sberg et al., 1979; 
Ruh et al., 1981), DNA (Majumdar & Frankel, 1978) and nu-
clear matrix, which consists of residual elements of the nu-
clear envelope and pore complexes, remnants of an internal 
fibrogranular network and residual nucleoli (Barrack et al., 
1977; Barrack & Coffey, 1980). For androgen-receptor com-
plexes interaction has been suggested with non-histones 
(Klyzsejko-Stefanowicz et al., 1976; Wang, 1978; Hiremath et 
al., 1981) which were further characterized as non-histone 
proteins with a basic overall charge (Mainwaring et al., 
1976). Glucocorticoid-receptor complexes have shown an affi-
nity for DNA (Bugany & Beato, 1977), and the progesterone 
receptor can interact with non-histones (Thrall & Spelsberg, 
1980). ·In addition, the purified A-subunit of the proges-
terone receptor showed interaction with DNA (Hughes et al., 
1981). The observations of Thrall & Spelsberg (1980), sug-
gesting that DNA alone is not the acceptor site, do not 
exclude the possible existence of a very limited number of 
DNA-sites with specific sequences as acceptor sites, as 
postulated by Yamamoto & Alberts (1975). In this respect the 
saturable binding to DNA containing limited nicks, which 
becomes non-saturable as nicks were increased (Thrall & 
Spelsberg, 1980; Hughes et al., 1981), may indicate that 
experiments showing non-saturable binding to DNA may reflect 
increased binding to DNA damaged during isolation (Buller & 
O'Malley, 1976; Simons et al., 1976). Moreover it has been 
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suggested that certain specific sequences ~n eukaryotic DNA 
preferentially bind the 
& Frankel, 1978) and 
(Payvar et al., 1981). 
estradiol-receptor complex (Majumdar 
the glucocorticoid-receptor complex 
In addition, androgen-receptor com-
plexes have been shown to recognize specific RNA having 
appropriate nucleotide sequences (Liao et al., 1980). The 
preferential binding of the progesterone receptor to single-
stranded DNA (Hughes et al., 1981; Schrader et al., 1981) 
and the definition of Champoux (1978) that a helix-destabi-
lizing protein displays preferential binding to single-
stranded DNA, led to the speculation (Hughes et al., 1981) 
that the receptor can act as a helix destabilizing protein. 
However, due to the artificial binding of receptors this 
speculation remains premature. Deterioration of the inte-
grity of chick oviduct chromatin increased its capacity to 
bind the progesterone-receptor complex, possibly v~a expo-
sure of previously "masked" acceptor sites (Webster & 
Spelsberg, 1979). In combination with observations that two 
or more different acceptor sites are present (Clark et al., 
1976; Spelsberg, 1976; Markaverich & Clark, 1979) it ~s 
tempting to 
the nucleus 
speculate that steroid-receptor complexes act on 
by initial binding to exposed regions of DNA 
with possible specific 
zation, followed by 
sequences 
increasing 
either directly or after some 
causing helix-destabili-
RNA-polymerase activity, 
other activation process 
initiated by steroid-receptor complexes. 
As reviewed by De Boer (1977) there is considerable evidence 
that chromatin consists of a condensed fraction (heterochro-
matin) and a less condensed fraction (euchromatin). Auto-
radiography on electron microscopic level of J 3 HJ Uridine 
incorporation into calf thymus nuclei has revealed that only 
the diffuse less condensed region of the chromatin is active 
i n RNA s y nth e s i s ( L i t t au e t a 1 • , 1 9 6 4 ) • Many a t t em p t s h a v e 
been made to fractionate the template into active and in-
active portions. The main approach in this fractionation has 
been to cleave the DNA or the chromatin by mechanical shea-
ring or sonication. The methods, however, transform the 
chromatin into a form which has little resemblance to the 
genome structure in vivo (Noll et al., 1975). For mainte-
nance of the structural integrity of the chromatin in vitro, 
the use of nucleases has been found to be superior over 
shearing by physical methods (Doenecke & McCarthy, 1976; 
Nicolini et al., 1976). Digestion of the chromatin by nu-
cleases therefore might better preserve the structural dif-
ferences between the template active and template inactive 
components of the chromatin. Three different nucleases, 
DNase I, DNase II and micrococcal nuclease, have mainly been 
used for these studies. DNase I digests preferentially 
active chromatin 1.n a random manner and can be used for 
studying transcriptionally active chromatin rather than as a 
method for the separation of template active and template 
inactive fractions (Weintraub, 1975). After dig~stion of the 
DNA of the chromatin to the extent that 10-20% of the DNA is 
acid-soluble (very small chromatin fragments dissolve in 
0.7 M perchloric acid at 0°C for 30 min), specifically 
expressed gene sequences have been released from the remai-
ning DNA. With this procedure non-expressed genes are still 
present 1.n the undigested chromatin. Ovalbumin gene sequen-
ces could be selectively degraded by DNase I digestion of 
the nuclei isolated from oviducts which actively expressed 
the ovalbumin gene. In contrast, when chicken liver nuclei 
in which the ovalbumin gene is not expressed, are digested 
with DNase I, no loss of albumin gene sequences had been 
observed (Garel & Axel, 1976). 
Separation of transcriptionally active and inactive 
chromatin has been introduced by Bonner and coworkers 
(1975). The method involves digestion of the chromatin with 
DNase II and precipitation of the template inactive chroma-
tin with MgC1 2 • A brief exposure to -this nuclease releases 
pieces of chromatin which contain approximat-ely 10% of the 
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DNA, but are enriched 20-fold in nascent RNA-chains, indica-
ting that the released fraction is enriched in template ac-
tive chromatin (Levy & Baxter, 1976). 
More specific cleavage of the DNA of the chromatin by 
nucleases can be 
(Kornberg & Thomas, 
performed 
1974). Mild 
with micrococcal nuclease 
digestion with this enzyme 
cleaves chromatin DNA to fragments of various lenghts by at-
tacking the linker DNA which connects the nucleosome cores. 
Template active chromatin is more accessible to micrococcal 
nuclease digestion than template inactive chromatin and more 
extensive digestion results ~n a chromatin fraction consis-
ting of mononucleosome cores more or less depleted of linker 
DNA. It is obvious that by controlled digestion, resulting 
in a series of nucleosomal oligomers and monomers, primarily 
from active chromatin, this enzyme offers a powerful tool 
for studying the distribution of steroid-receptor complexes 
over the chromatin. 
Recently, it has been reported that certain "high mobi-
lity group" proteins, HMG 14 and 17, bind specifically to 
the nucleosomes which are active in transcription (Albanese 
& Weintraub, 1980; Weisbrod et al., 1980). HMG-depleted nu-
cleosomes, orginally active ~n transcription, have been 
separated from the bulk of the inactive nucleosomes present 
~n the population with immobilized HMG 14 and 17 (Weisbrod 
& Weintraub, 1981). It remains to be established, however, 
whether this procedure, which involves chromatin pretreated 
with 0.35 M NaCl to remove the HMG 14 and 17, ~s still su~­
table for steroid-receptor-acceptor studies. 
Several studies with specific nucleases have shown that the 
steroid-receptor complex is enriched ~n the transcriptio-
nally active fraction of the chromatin. This has been found 
for the estradiol-receptor complex (Hemminki, 1977; Alberga 
et al., 1979; Scott & Frankel, 1980; Schoenberg & Clark, 
1981) for the glucocorticoid-receptor complex (Andre et al., 
1980) and for androgen-receptor complexes (Davies et al., 
1980; Weinberger & Veneziale, 1980; Hiremath et al., 1981). 
There are some reports suggesting that the steroid-receptor 
complex can be located also on the nucleosomes (Massol et 
al., 1978; Senior & Frankel, 1978; Scott & Frankel, 1980), 
but location on the internucleosomal regions (Senior & 
Frankel, 1978; Rennie, 1979; Davies et al., 1980; Rochefort 
et al., 1980; Scott & Frankel, 1980) appears more likely. 
The mechanism for replenishment of 
they have acted 
steroid receptors 
in the cytoplasm, once 
steroid-receptor complex, has 
estradiol receptor system. In 
estradiol action have widely 
been 
these 
on 
studied 
studies 
the genome 
mainly ~n 
antagonists 
been used. Anti-estrogens 
as 
the 
of 
are 
compounds which prevent estrogens from expressing their full 
e f f e c t s on e s t r o g en target t i s s u e s . Wh i 1 e they ant a g on i z e 
estrogen-stimulated tissue growth, they can be considered as 
partial agonists (Katzenellebogen et al., 1978). This par-
tial agonist action is a result of the translocation of the 
anti-estrogen-receptor complex to the nucleus and subsequent 
interaction with the genome. Following initial stimulation 
of tissue growth, e.g. by the non-steroidal anti-estrogens 
nafoxidine and tamoxifen, replenishment of cytoplasmic re-
ceptors is much slower than observed with agonists like es-
tradiol (Clark et al., 1973; Capony & Rochefort, 1975; 
Horwitz & McGuire, 1978). Therefore, multiple cycles of 
nuclear binding and stimulation are largely retarded (Clark 
et al., 1978). With agonists, like 17B-estradiol, receptors 
~n the cytoplasm are gradually replenished, resulting ~n 
control receptor levels after 11-16 h (Sarff & Gorski, 
1 9 7 1 ; Anders on e t a 1 . , 1 9 7 4 ) . I t has b e en shown that 
replenishment after administration of some "short-acting" 
estrogens ~s very rapid. After a single injection of 
2-hydroxy-estradiol, replenishment is complete within 3 h 
(Martucci & Fishman, 1979) and after injection of 16 a 
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estradiol within 4 h (Kassis & Gorski, 1981). These latter 
authors concluded that estrogen receptor replenishment ~s 
entirely due to receptor recycling rather than that reple-
nishment is partly the result of resynthesis of receptors 
(Mester & Baulieu, 1975; Jungblut et al., 1979). Injection 
o f 1 7 i3 - e s t r ad i o 1 into immature rats cause s a dec rea s e ~ n 
total uterine receptor content (Zava et al., 1976; Kassis & 
Gorski, 1981) and ~n studies with MCF-7 human breast cancer 
cells, treated with 17S-estradiol, a rapid loss of total 
cell receptor content has been observed after receptor accu-
mulation in the nucleus (Horwitz & McGuire, 1978, 1980). 
This approximately 70% loss (after 3-5 h) of total receptor 
content without reappearance in the cytoplasm has been 
termed "processing" (Horwitz & McGuire, 1978). After 3-5 h 
incubation nafoxidine-bound nuclear receptors appear not to 
have been processed at all and with tamoxifen only 30% of 
nuclear receptors are lost before the level of nuclear 
receptors remains constant (Horwitz & McGuire, 1978). This 
apparent loss of receptors could be due to a change in the 
receptor molecule and as a result the receptor can not bind 
steroid and therefore not be measured anymore. This hypo-
thesis is supported by recent observations of Auricchio and 
associates (Auricchio & Migliaccio, 1980; Auricchio et al., 
1981a,b,c) suggesting that the long half-life or nuclear 
retention of the anti-estrogen-receptor complex versus the 
short half-life of the estradiol-receptor complex in uterine 
nuclei in vitro is the result of the ineffectivity of a nu-
clear factor to inactivate the anti-estrogen-receptor com-
plex. These authors showed that this nuclear factor ~s pro-
bably a phosphatase, which ~s not present ~n non-target 
tissue nuclei, and changes part of the estrogen receptor to 
a form which can not bind estradiol anymore. Experiments 
performed with the partially purified phosphatase and isola-
ted calf uterine estrogen receptor suggest that the receptor 
itself might have been dephosphorylated 
1981b'c). The phenomenon of processing 
(Auricchio et 
as described 
al., 
by 
Horwitz & McGuire (1978, 1980) can be explained by these 
assumptions. After recycling to the cytoplasm the dephos-
phorylated receptor protein is ready to be phosphorylated 
again to fulfil a further cycle of activation, translo-
cation and interaction with the genome. Additional confir-
mation of these hypothesis might be drawn from (a) experi-
ments with purified progesterone receptors, which appeared 
to be good substrates for phosphorylation (Weigel et al., 
1981), and from (b) studies with the glucocorticoid recep-
tor which requires phosphorylation of the receptor before 
interaction with the steroid 
1977a'b; Litwack et al., 1980). 
occurs (Nielsen et al., 
From the results in the literature, described in this 
and preceeding chapters, it is tempting to speculate that 
the possible events involved in the mechanism of action of 
steroids follow the hypothetical scheme presented in figure 
2.3, with as a major characteristic the involvement of a 
phosphorylation-dephosphorylation process of the receptor. 
At the moment, however, there is no evidence available that 
this process is applicable to any of the different steroid 
hormone receptors. Especially, with respect to androgen 
receptors, little is known at the moment about the processes 
occuring before, during, and after binding of the androgen-
receptor complexes to nuclear acceptor sites. 
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Figure 2.3: Possible events involved in the mechanism of 
action of steroid hormones. 
After recycling from the nucleus the dephosphorylated unoccu-
pied receptor interacts with a low molecular weight inhibitor 
of activation in the cytoplasm. This complex can be phosphory-
lated by a kinase resulting in a phosphorylated receptor which 
is able to bind steroid. In vitro, the non-activated steroid-
receptor complexes are stabilized by molybdate, either directly 
or via inhibiting a phosphatase in the cytoplasm. This phospha-
tase either dephosphorylates the receptor. protein which results 
in rapid dissociation of the labile dephosphorylated steroid-
receptor complex, or this phosphatase dephosphorylates a pro-
tease which is active in dissociating aggregrated steroid-
receptor complexes if the protease is in its dephosphorylated 
form. The non-activated steroid-receptor complexes are activa-
ted by dissociation of the low molecular weight inhibitor from 
the phosphorylated steroid-receptor complexes by e.g., dialysis, 
increase in temperatures or high salt concentrations (in vitro). 
The activated steroid-receptor complexes translocate to the 
nucleus where they interact with the chromatin. The steroid-
receptor complexes are released by indirect action of a phospha-
tase which is present in the nucleus and dephosphorylates the 
receptors. This dephosphorylation results in rapid dissociation 
of the steroid-receptor complexes, resulting in unoccupied 
receptors which are unable to bind to the chromatin. The unoccu-
pied receptors recycle to the cytoplasm where they are ready to 
fulfil a further cycle as has been described above. Alternati-
vely, the activated steroid-receptor complexes can be transfor-
med to a non-chromatin binding form by pyridoxal 5 '-phosphate 
which blocks the chromatin binding site. 
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Chapter 3 
ANDROGEN RECEPTORS IN HUMAN PROSTATIC TISSUE 
This chapter is a revlew on the measurement of androgen 
receptors ln human prostatic tissues. A nuclear androgen 
receptor assay has been developed and the prognostic value 
of a nuclear androgen receptor assay for clinical applica-
tions will be discussed. 
3.1.1 Introduction 
A correlation between the content of steroid recep-
tors in mammary tissue and the response to endocrine therapy 
in advanced breast cancer was first described by Jensen and 
coworkers (1971). As reviewed by McGuire et al. (1975), en-
docrine therapy lS essentially useless in patients who were 
"receptor negative" while 60% of "receptor positive" pa-
tients responded to such therapy. Receptor positive patients 
appear to respond poorly to chemotherapy (Lippman et al., 
1978). On basis of these results on mammary cancer it is 
reasonable to investigate whether a similar correlation 
might exist for human prostatic carcinoma, the second most fre-
quently occurring malignant disease in males ln the western 
world. To investigate this possibility it would be necessa-
ry to estimate receptors in human prostatic tissue. 
The growth and function of the prostate are primarily 
dependent on androgenic stimulus. The major circulating an-
drogen, testosterone, is almost completely of testicular 
origin (Lipsett, 1970). After castration the prostate atro-
phies rapidly, but retains its normal function following 
androgen stimulation (Bruchovsky et al., 1975). 
The human prostate can be divided into a central or 
periurethral part and a dorsal or peripheral part (McNeal, 
1972). Benign prostatic hyperplasia (BPH) is extremely rare 
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in the peripheral parts of the gland (Moore, 1943). Pros-
tatic carcinoma, however, starts predominantly (97-98%) ln 
the peripheral parts of the prostate (Dube et al., 1973). 
Clinical response of BPH to anti-androgen therapy has 
been reported (Scott, 1971) and 75-80% of all prostatic 
carclnomas appear to respond to endocrine management 
(Fergusson, 1972). In this respect is was of importance to 
investigate the possibility if the estimation of androgen 
receptors could assist ln selecting patients, with non-
operable tumors, who will benefit from endocrine treatment. 
Receptor negative patients might then be treated immediately 
with other therapies, like irradiation with 125 1 (Whitmore 
1972). Also a combination of therapies should be considered 
(Sinha et al., 1977; Chisholm, 1981). 
3 .1. 2 
Several aspects of estimating steroid receptors have 
been discussed. The principal intracellular androgenic 
hormone in rat prostate has been identified as 5 a -dihydro-
testosterone (DHT) (Anderson & Liao, 1968; Bruchovsky & 
Wilson, 1968). From this finding, the first attempts to 
characterize human prostatic androgen receptors employed 
radioactive DHT (Hansson et al., 1971; Mainwaring & Milroy, 
1973; Geller et al., 1975). Difficulties arose, however, 
when it was found that cytosols of human prostates contain 
Sex Hormone Binding Globulin (SHBG), probably as a result 
of plasma contamination, which binds DHT with equal affi-
nity as the androgen receptor (Steins et al., 1974; Cowan 
et al., 1975). Hence, using DHT as ligand, the amount of 
cytoplasmic androgen receptor may be overestimated due to 
the additional binding to SHBG. A second problem has been 
the high endogeneous content of DHT ln human prostatic 
tissue (Siiteri & Wilson, 1970), expressed in ng DHT/g 
tissue for normal, BPH and carcinoma tissue: 2.3, 3.9 and 
5.0, respectively (Geller et al., 1979). With such high 
concentrations of steroids (ratio DHT/receptor higher than 
10/l), it might be expected that most androgen receptors are 
occupied and as a result are predominantly located ln the 
nucleus (Mainwaring, 1977). An additional problem lil measu-
ring the remaining occupied receptors in the cytoplasm ls 
the time requireci to exchange addeci labelled steroid for 
endogeneously bound DHT at low temperatures. This large ln-
cubation time of cytosol samples causes degradation of re-
ceptors by the presence of significant amounts of proteo-
lytic enzymes ln ':hese cytosols. with DHT as exchange li-
gand, 
result 
such long incubation -~imes of cytosol samples also 
in metabolism of DHT, -which occurs rapidly 
(Attramadal et al., 1975; Shicla et al. 
temperatures (Snochowski et al., 1977) 
1975), even at low 
Most of the problems 
are associa·ced v1ith the measurement of cytoplasmic re.cep-
tors 5 rat:her than of nuclear :-eceptcrs, because :he 
nuclear extracts no SHBG and no metabolism of DHT have been 
found, 
Foe kens 
whereas proteolytic 
& J. Bolt-de Vries, 
degradation 
unpublished 
lS negligible 
observations) 
(J .A. 
Hew-
ever, when the synthetic androgen methyltrienolone (Rl88l) 
lS used :Eo: labelling of recep·cors, many of these obstacles 
can be ove-:-come by measuring cy·coplasmic receptors~ Rl88l 
has che grec:_c advantage or binding -co intracellular recep-
tcrs but: not -co ShBG and it 'c not metabolized (Bonne & 
Reynaud, l9"75, 1976: Snccho,;rski et aL 1977; Menon et al., 
978). rl complication or using Rl88l is its ability to bind 
to proges"Cerone receptors (Zava et al. 1979), which have 
been reported 1:0 be present in human prostate cytosol (Cowan 
et al., 1977; Tilley et al. 1980) and also, but to a lesser 
extent ln T1'JClear extracts (Sirett & Grant, 1978 There-
fore, precautions have tc be taken and samples should be 
labelled ln the presence of a 500-fold excess of the gluco-
corcicoid t:-iamcinolone ace"tonide which appears to block 
for Rl88l binding with-
Rl88l to the androgen 
compl~tely the progesterone receptor 
out interfering with the binding of 
receptor. 
In conclusion, the estimation of androgen receptors 
Jn cytosols of human prostatic tissue lS associated v1ith 
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several problems which, ln addition to the expected pre-
dominantly nuclear localization of the receptor, render the 
measurement of nuclear androgen receptors more promising. 
3. 1. 3 
The literature up to 1977 concerning androgen recep-
tors ln human prostatic tissue, has been 
Cl977a). 
reviewed exten-
sively by Menon and coworkers Generally used 
assay procedures involve gel filtration, charcoal separa-
tion, sucrose gradient centrifugation, lOn exchange chroma-
tography, electrophoresis, protamine sulphate precipitation 
or equilibrium dialysis. The large variation of receptor 
values ln cytosol samples of BPH tissue (0-4,000 fmol/g 
tissue) can be attributed completely to the complicating 
factors associated with estimating these receptors, as has 
been dis cussed ln chapter 3 .1. 2. The amount of nuclear an-
drogen r e c e p tors , f i r s t rep or ted by Menon e t a 1 . ( 1 9 7 7b ) , 
appeared to be 10-60 fmol/g tissue. In more recent studies 
several laboratories have also measured nuclear androgen 
receptors. Recently reported results on the amounts of 
androgen receptor ln BPH tissue are listed in table 3.1 for 
cytosol receptors and ln table 3.2 for nuclear receptors. 
Only the results obtained with methods which are moderately 
reliable (using experimental conditions not likely to intro-
duce artifacts) have been considered in the tables. The re-
sults indicate, tha:t most receptors are located in the nu-
cleus (e.g. Sirett & Grant, l978b: 404 fmol/g tissue ln 
nuclear extracts compared with 141 fmol/g tissue in cyto 
sols). It is difficult to express all the results ln the 
same way, e.g. as sites/cell, because the different groups 
used different procedures in preparing cytosols and nuclear 
extracts, which may have influenced the estimated amounts 
of protein and DNA, which were used to express the amount 
of receptors. Although the ratio of nuclear versus cyto-
plasmic receptor is approximately 3:1, it still has to be 
evaluated whether this lS the actual distribution. In a 
recent report (Trachtenberg et al., 1981) it has been esta-
incubation 
conditions fmol fmol fmol dissociation 
time/temp. receptor/g receptor /mg receptor img constant 
'Literature Assay (Ligand) 'tissue protein DNA (nMl 
Sirett & LH-20 20h/1SOC 141±38 0.85±0.26 
Grant (R1881) 
(1978b) 
Sirett LH-20 20h/tSOC s: 27±5 368±77 1.10±0.19 
et al. (R1881l e: 30±6 110±11 0.~8±0. 13 
(1980) 
Krieg Agar 24h/OOC 12.3 
et al. 
(1977) 
Hicks & DCC 20h/4°C 48±22 1. 3±0. 6 
Walsh (R1881l 
(1979} 
LH-20. Sephadex gel filtration s: stromal cells 
Agar, agar gel electrophoresis e: epithelial cells 
DCC. dextran coated charcoal 
Table 3.1: Cytoplasmic androgen receptors in human BPH-tissue. 
incubation 
conditions fmol fmol fmol receptor dissociation 
time/temp. receptor/g receptor /mg receptor /mg sites/ constant 
Literature Assay (Ligand) tissue protein DNA cell (nM} 
Sirett & LH-20 24h/150C 404±43 3. 97±0. 73 
Grant (DHT} 
(1978b) 
Sirett LH-20 24h/150C s: 556±76 2. 14±0. 29 
et al. (DHT} e: 697±182 1. 75±0. 29 
( 1980} 
Menon PSP 20h/40C 10-60 3. 4 
et al 
(1977b) 
(DHT} 
Menon DCC 20h/0°C 67.5 2. 6 
et al. (R1881} 
( 1978} 
Hicks & DCC 20h/4°C 104 2.8±0.8 
Walsh (R1881} 
( 1979} 
Lieskovsky & DCGF 18h/4oc 1400 4.5 
Bruchovsky (DHT} 
( 1978} 
Shain DCC 24h/15°C 0.31±0.4 
et al. (R1881} 
( 1978} 
LH-20. Sephadex gel filtration s: stromal cells 
PSP, protamine sulphate precipitation e: epithelial cells 
DCC, dextran coated charcoal adsorption 
DCGF. dual column ( G 25-G 200} gel feltration 
Table 3.2: Nuclear androgen receptors in human BPH-tissue. 
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blished that the amount of estimated cytoplasmic receptors 
can be increased almost four fold by addition of molybdate 
and a protease inhibitor, phenylmethylsulphonylfluoride 
(PMSF), prior to the incubation. This 
the figures listed 1n tabel 3 .l could 
suggests that also 
well be underesti-
mations of the actual receptor values. For this and several 
already mentioned reasons it might be more meaningful to 
estimate 1n human prostatic tissues nuclear rather than 
cytoplasmic androgen receptors, with the ultimate goal to 
study whether a possible relation exists between the amount 
of receptors and the response to endocrine management. 
3. 1. 4 ~E~g~~~!i~-~~!~~-~!-~~!i~~!i~g-~!-~g~!~g~g_E~~~E!~E~ 
i~_!E~~E~~~E-~i_EE~~~~~i~-~i~~~~~~ 
Endocrine treatment, introduced by Huggins & Hodges 
(1941), has been a main therapy for prostatic carcinoma and 
75-80% of all prostatic carcinomas respond to estrogen 
therapy (Fergusson, 1972). A complication of estrogen 
therapy 1s the high rate of cardiovascular complications 
(reported by the Veterans Administrative Cooperative Urolo-
gical Research Group, 1967). Consequently, castration has 
become more widely used as a primary form of therapy 1n 
prostatic carcinoma and this treatment 
least as effective as estrogen treatment 
growth of prostatic carcinoma (Fergusson, 
of endocrine manipulations in patients 
appears to be at 
in controlling the 
1972). Other forms 
with prostatic car-
cinoma are addition of anti-androgens like, cyproterone ace-
tate (Isuguri et al., 1980) megestrol acetate and medroxy-
progesterone (Rafla & Johnson, 1974; Johnson et al., 1975), 
and flutamide (Sogami & Whitmore, 1979). Also corticoids 
have been used with some success (Miller & Hinman, 1954). 
It remains possible, in analogy with the endocrine 
management of breast tumors, that the 20-25% non-responders 
to endocrine therapy of prostatic carcinoma are "androgen 
receptor negative". Some attempts have been made to find a 
correlation between androgen receptor content and the res-
ponse to endocrine management. Wagner & Schultz (1978) 
concluded from their series of patients that no correlation 
existed between androgen receptor content and the response 
to endocrine therapy. In contrary, Ekman and associates 
(1979), reported a good correlation between cytoplasmic an-
drogen receptor levels and the response of the tumors to 
endocrine management. These conflicting results might be due 
to the inacuracy of the measurements of cytoplasmic recep-
tors described ~n the previous section. Therefore, a relia-
ble androgen receptor assay (preferably for nuclear recep-
tors) could become increasingly important because the esti-
mation of androgen receptors in prostatic carcinoma tissue 
may assist in selecting the appropriate therapy for patients 
suffering from this disease. 
~~!!~~!~~~~~~!g_g~E2!i~-2~~-~~!~~~!~~~-~!_!g~-~~~£~~ 
~i-~~~~igg_~~!~~-~~!g_~~i!~!~~!-~~!g~~~~ 
The conditions for assay of nuclear androgen recep-
tors ~n human prostatic tissue has been evaluated with BPH 
tissue, which was available in sufficient amounts, and could 
be stored at -80 °C. 
A comparison was made between the estimated amounts 
of receptors using protamine sulphate precipitation, sepha-
dex LH-20 gel filtration and agar gel electrophoresis as 
techniques for specific isolation of receptors. Ratios of 
the amount of receptors found with these three different 
techniques were 100:88:61. Hence, protamine sulphate preci-
pitation was accepted as most suitable for routine assay. 
Extraction of androgen receptors from a nuclear pellet with 
a heparin (1 mg/ml) containing buffer appeared to be twice 
as e f f i c i en t a s the c o mm on 1 y u s e d 0 . 4 M K C 1 ex t r a c t i on 
(82 ± 7 and 49 ± 2 fmol/mg protein respectively, which corre-
47 
48 
sponds with 2333 ± 192 and 1005 ± 31 molecules/nucleus; 
means± S.D., n=5). 
For clinical application a method has been evaluated 
which involves extraction of nuclear pellets with a heparin 
containing buffer (1 mg/ml), exchange labelling of nuclear 
extracts for 20 h at 10°C and estimation of receptor-
bound labelled DHT after protamine sulphate precipitation. 
Detailed procedures of this assay are described in appendix 
paper I. 
The applicability of the reported nuclear androgen 
receptor assay (appendix paper I) for biopsy-size specimens 
of BPH tissue has been investigated in a subsequent report 
(Blankenstein et al., 1982). It appeared that it is techni-
cally possible to estimate nuclear androgen receptors in as 
little as 25 mg of prostatic tissue. However, the inhomo-
geneous distribution of androgen receptors 1.n the tissue, 
excludes the possibility to obtain a meaningful ;-ecei?tor 
value on a single biopsy of BPH tissue which contains both 
epithelial and stromal cells. 
It remains to be established whether biopsy-size 
specimens of prostatic carcinoma, which consists almost 
completely of epithelial ce'lls, gives a more homogeneous 
distribution of the androgen receptor over the tissue. 
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Chapter 4 
CHARACTERIZATION AND PURIFICATION OF ANDROGEN RECEPTORS 
The lack of purified androgen-receptor complexes is 
one of the most serious handicaps for the progress of re-
search on the mechanism of action of androgens. The availa-
bility of purified androgen-receptor complexes is of extreme 
importance for a.o. studies on receptor site-ligand inter-
actions, for the determination of the structure of the hor-
mone binding site and for investigating receptor proteins as 
metabolic regulators, especially of geneti·c transcription. 
Unless highly purified preparations of androgen-receptor 
complexes are used, the interpretation of experiments in 
vitro are always open to criticism and to difficulties in 
interpretation. For example, nucleases 
vators and inhibitors could create 
or unspecified acti-
serious experimental 
artifacts when studying interaction of androgen-receptor 
complexes with chromatin in cell-free conditions. For fur-
ther study of the mechanism of action of androgens and for 
clinical applications the availability of antibodies against 
the receptor is desirable. Fortunately, the recently deve-
loped monoclonal antibody technique does not require a 100% 
pure receptor preparation to isolate specific antibodies. 
Hence, it may be possible that with an approximately 1-10% 
pure receptor preparation an antibody against androgen 
receptors may become available in the near future. 
The purification 
associated with ser~ous 
are notoriously labile 
of androgen-receptor complexes is 
difficulties. The receptor proteins 
(Mainwaring, 1969) and tissues con-
taining androgen receptors contain very high proteolytic 
activity which resists commonly used inhibitors, such as 
PMSF (Mainwaring, 
minute quantities 
40 11 g of receptor 
1978). The receptors are present in only 
~n androgen target cells (approximately 
protein is present ~n a kilogram of rat 
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prostatic tissue; Mainwaring & Irving, 1973). The only 
reliable means for 
association with a 
bound radioactive 
detecting the receptor protein is its 
labelled ligand and dissociation of the 
ligand must be prevented. Therefore, 
fractionation methods must be rapid to prevent dissociation 
and denaturation of the labile androgen-receptor complex. 
In addition, the resolution and specificity of conventional 
methods of protein fractionation have been found insuffi-
cient, sofar, for androgen receptor purification. Apart from 
a single study (Mainwaring & Irving, 1973) in which, in an 
isolation procedure on a small scale, a 5,000 fold purifi-
cation of androgen receptors from rat prostates was reached 
mainly on basis of the high separation power of a prepara-
tive iso-electric focussing system, no futher reports on the 
purification of androgen receptor have been published. 
In early studies, partial purification of estrogen 
and progesterone receptors by ammonium sulphate precipi-
tation and 
(De Sombre 
DEAE-sephadex chromatography has been 
& Gorell, 1975; Puca et al., 1975; 
achieved 
Schrader, 
1975). In addition, purification of the native 
receptor complex with heparin-sepharose has 
successful (Molinari et al., 1977). Steroid 
estradiol-
been very 
receptors, 
however, possess both a steroid binding-site and a DNA 
binding-site. Therefore, more recently, advantage has been 
taken of the property of steroid receptors to interact with 
DNA and DNA-like structures (e.g. phosphocellulose) once the 
receptors are in their activated form (as discussed in chap-
ter 2.2.3). With these kind of gels, considerable success 
has been obtained in the purification of receptors for es-
tradiol (Eisen & Glinsmann, 1978), for glucocorticoids 
(Wrange et al., 1979) and for progesterone (Schrader et a1., 
1977; Coty et al., 1979; Weigel et al., 1981). 
has 
tage 
Purification of some 
been accomplished with 
has been taken of the 
steroid binding-site of the 
matrices with immobilized 
steroid receptors to homogeneity 
affinity chromatography. Advan-
availability of an unoccupied 
receptor, 
steroids 
and in these 
were used. 
studies, 
Notwith-
standing the successes obtained with affinity chromatography 
of several steroid receptors (Coffer et al., 1977; Kuhn et 
al., 1977; Govindan & Sekeris, 1978; Sica & Bresciani, 1979; 
Govindan, 1980; Greene et al., 1980; Smith et al., 1981), 
this method, which requires that the receptor has to be pre-
sented to the columns 1n its unoccupied form, has not. been 
SBccessful thus far for the isolation of androgen receptors 
(Mainwaring, 1978; 
Johnson, 1980). 
Mulder & Vrij, 1979; Mainwaring & 
In this thesis, experiments are described concerning 
purification procedures, other than affinity chromatography, 
and characterization of androgen receptors from ram seminal 
vesicles. The characteristics of these receptors are com-
pared with the characteristics of androgen receptors from 
rat prostate. 
Ii:~~~~-=- Seminal vesicle tissue from adult rams were 
removed as soon 
was immediately 
as possible 
frozen at 
after killing the animals and 
-20° C. After transportation 
from the 
stored at 
slaughterhouse 
-80°C. When 
to the laboratory the tissue was 
indicated fresh tissue was used 
after transportation on ice to the laboratory. Rat prostate 
tissue was used 1 day after castration. 
Purification columns: 
------------------------
DEAE-sephadex (A-50), 
2' ,5'-ADP-sepharose, poly U-sepharose, carboxymethyl-
sepharose, and sephadex LH-20 were obtained from Pharmacia, 
Sweden. DNA-cellulose was prepared according to Alberts & 
Herrick (1971) and heparin-sepharose by the procedure of 
Cuatrecasas (1970). Bio-Gel P-6DG was purchased from Bio-Rad 
Richmond, California, USA, phosphocellulose Laboratories, 
from Whatman Inc., U.K., and U1trogel ACA-44 from LKB 
Instruments Ltd., U.K. 
were 
~I~~E~~~~~=--~~~--~~~~~~~--~~~~~~~~~: All procedures 
performed at 0-6°C. For preparation of cytosols, 
containing cytoplasmic receptors, 
stored at -80°C or fresh ventral 
ram seminal 
prostates of 
vesicles 
rats one 
day after castration were used. Minced tissue was homo-
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genized ~n 2-3 volumes of TEDG buffer ( 10 mM Tris-HCl, 1. 5 
mM ED T A , 1 . 5 mM d i t h i o t h r e i to 1 w i t h 1 0% g 1 y c e r o 1 ; b u f f e r A , 
pH 7.4) either with a Waring blendor for 3 x 20 s or with 3 
x 10 s strokes of an Ultraturrax tissue-homogenizer (in some 
experiments, as indicated, sodium molybdate was added to the 
homogenization buffer). The homogenate was centrifuged for 
45 min at 96,000 x g av in a Beckman SW-27 rotor and the 
supernatant was designed as "cytosol". For labelling of 
cytoplasmic receptors, cytosols from rat prostates were 
incubated for 2 h at 0°C with 10 nM \3H\R1881 (spec. act. 87 
Ci/mmol) or with 10 nM \3H\DHT (spec. act. 103 Ci/mmol) 
in the absence and presence of a 100-fold excess nun-radio-
active steroid to correct for non-specific binding. Cytosols 
from seminal vesicles of rams were incubated for at least 
20 h at 6-10°C with concentrations of radioactive ste-
roids as indicated. For labelling of nuclear receptors, 
tissue m~nces were incubated for 
minimal essential medium with 
1 h at 
20 nM 
37°C in Eagle's 
\ 3H\testosterone 
(spec. act. 93 Ci/mmol) ~n the absence and presence of a 
100-fold excess non-radioactive steroid to correct for non-
specific binding. The tissue was homogenized, as described, 
in buffer B (buffer A without glycerol) and the 700 x g 
nuclear pellet was prepared .. The -pellet was washed with 
buffer B containing 0.2% Triton X-100 and subsequently 
twice with buffer B. A nuclear extract was prepared by 
extracting the washed nuclear pellet with 0.4 M KCl in 
buffer B (pH 8.4) for 1 h at 0°C and centrifugation for 
15 min at 10,000 x g. 
§~£IQ~~-g£ggi~g!_f~g!£if~g§1i9g1 An aliquot of 250 ~1 
was centriguged at 1 °C in 4. 8 ml -of linear 10-30% (w/v) 
sucrose gradients for 210 min at 370,000 x g ~n a Beckman 
av 
VTi-65 rotor, resulting in a good separation between 3 S and 
9 S sedimenting entities. Alternatively, 200 ~1 samples 
centrifuged at 1 °C ~n 4.0 ml of linear 5-20% (w/v) 
were 
su-
erose gradients (in buffers without glycerol) for 18 h at 
310,000 x gav in a Beckman SW-60 rotor for characterization 
of the 3-5 S region and (in buffers with glycerol) for 16 h 
at 150,000 x gav for characterization of the 7-10 S region 
of the gradients. 
~g~E--~~~-~1~~~E22~2E~~i~~ Agar gel electrophoresis 
was perfromed as described by Wagner (1972). Free steroid 
migrates to the cathodic region of the agar gel whereas 
receptor-bound steroid migrates to the anodic region of the 
gel during electrophoresis of 50 )11 samples for 90 min at 
130 rnA at 0°C. 
filtration was 
Ginsberg et al. 
perfromed 
(1974). 
Sephadex LH-20 
essentially as described 
gel 
by 
Aliquots of 50 or 100 pl were 
applied on small columns of Sephadex LH-20 (Pasteur pipet-
tes) and protein-bound steroids were elute.d in the void 
volume fractions, whereas free steroid was separated by gel 
exclusion chromatography. 
This method was 
performed as described by Chamness et al. (1975). A pro-
tamine sulphate concentration of 1 mg/m1 was used to pre-
cipitate the protein-bound steroids for 10 min at 0°C. 
For partially purified receptor preparations the modified 
method as described by Mulder et al. (1981) was used. The 
modification involves the addition of 10 mM pyridoxal 
5'-phosphate prior to the precipitation assay. After centri-
fugation and washing of the precipitates the radioactivity 
Ln the pellets was counted after dissolving the precipitates 
Ln 0.5 ml Soluene for 10 min at 60°C. 
QQ1~~g_£h!2~~!Qg!~PhY~ Column chromatography was per-
formed as described by Mulder et al. (1979) with the notable 
exception that Ln some cases a gradient of increasing KCl 
concentrations was used for elution of receptors from the 
column. When indicated, also the time of incubation with the 
column material was varied. 
~.::~!~i!: __ d_e_t_e_r_m_i_n_a_t_i_o_n_: Protein was estimated accor-
ding to Bradford (1976). 
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~~g~~~--s_c_iy._t_i_l_l3_t_i_o_:J-__ ~<:_':_~t:_~~~:_ Samp 1 e s for counting 
of radioactivity were mixed with 10 ml of Insta-Gel (Packard 
Instrument) as scintillation cocktail. Protamine sulphate 
precipitates were dissolved in 0.5 ml Soluene for 10 min at 
60 °C and counted 1n 10 ml of Insta-Gel after addition 
of 1% (v/v) acetic acid and 0.1% butylated hydroxytoluene. 
from ram seminal vesicles 
As has been discussed in chapter 4.1.1, the availa-
bility of a purified androgen receptor preparation appears 
necessary for further studies on the mechanism of action of 
androgens. The limited amounts of androgen receptor present 
and the small size of androgen target tissues render the 
rat prostate an unattractive source for androgen receptor 
purification. Cytoplasmic androgen receptors are present in 
seminal vesicles of rat and mouse (Mainwaring & Mangan, 
1973) and in ram testis (Monet-Ki.intz et al., 1979). We have 
investigated the presence of androgen receptors 1n ram 
seminal vesicles as a possible source for large scale recep-
tor purification. 
Nuclear androgen receptors from ram seminal vesicles 
were identified by sucrose gradient centrifugation and by 
agar gel electrophoresis. A specific androgen-binding pro-
tein sedimented at 3 Son sucrose gradients (figure 4.1A) 
similar to the nuclear androgen receptors from rat prostate 
(figure 4.1B). Agar gel electrophoresis at pH 8.4 showed an 
electrophoretic mobility of bound radioactivity towards the 
anodic region of the agar gel (figure 4.1C). Similar elec-
trophoretic behaviour has been observed for androgen recep-
tors extracted from nuclei of rat prostates (figure 4.1D). 
BSA B a.s. c D 
dpm 
X 10- 2 ~ ~ dpm X 10- 2 dpm X 10-2 
6 6 
10 20 10 20 
bottom bottom 
10 
fractions 
20 
top fractions fractions + 
Figure 4.1: Sucrose gradient centrifugation and agar gel elec-
trophoresis of nuclear androgen receptors from rat 
prostates and ram seminal vesicles. 
Labelled nuclear extracts of rat prostates and ram seminal 
vesicles were analysed with sucrose gradient centrifugation 
(A and B, respectively) or agar gel electrophoresis (C and D, 
respectively). 
- , total binding; o----o , non-specific binding; BSA, 
position of sedimentation marker, bovine serum albumin (4.6 S) 
after centrifugation·; a. s., "application site", sample applied 
at the start of electrophoresis; + and , anodic region, 
cathodic region of the agar gel respectively; free steroid was 
present in fraction 2-6 and protein-bound steroid was present 
in fraction 9-13. 
Seminal vesicles were obtained from a group of non-
castrated 
measured*) 
rams. Approximately 700 pg androgen has been 
For this reason binding-studies required long 
incubation times to allow the added radioactive steroid to 
be exchanged with the endogeneously receptor-bound non-
radioactive steroid. Under these conditions androgen 
receptors are very labile and especially a 7-12 S sedimen-
ting form of the receptor from ram seminal visicles, on 
sucrose gradients, could never be demonstrated when no 
~)Analysis performed by Dr. F.H. de Jong. 
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Figure 4.2: Sucrose gradient centrifugation and agar gel elec-
trophoresis of cytoplasmic androgen receptors. 
Labelled cytosols of ram seminal vesicles, prepared in the pre-
sence of 50 mM molybdate, were analysed with sucrose gradient 
centrifugation (A) and agar gel electrophoresis (B). Labelled 
cytosol of rat prostates was analysed with agar gel electropho-
resis (C). I and II, positions of sedimentation markers Y-glo-
bulin (7.2 S) and BSA (4.6 S), respectively. For further details 
see the legend to figure 4.1. 
precautions were taken. After addition of molybdate, which 
can stabilize the androgen receptor from rat prostate 
(Gaubert et al., 1980) as well as other steroid receptors 
(Chen et al., 1981; Miller et 
!JH! Rl881-binding proteins ~n 
al., 1981), 
cytosols from 
two distinct 
ram seminal 
vesicles, one sedimenting at approximately 9 S and one at 
about 3 S, could be demonstrated by sucrose gradient cen-
trifugation (figure 4.2A). Apart from a small shift in sedi-
mentation values, similar profiles have been obtained for 
sucrose gradients of cytoplasmic androgen receptors from rat 
prostate (Mulder et al., 1980). Analysis by agar gel elec-
trophoresis shows an electrophoretic mobility towards the 
anodic reg~ on of the gel, both for cytoplasmic receptor 
from ram seminal vesicle and from rat prostate (figure 4.2B 
and 4.2C, respectively). 
A general characteristic of steroid receptors is 
their ability to bind to DNA-like matrices once the recep-
tors are in their activated state (Fleischman & Beato, 1979; 
Litwack et al., 1980; Moudgil & John, 1980). It was inves-
tigated whether this also holds for the androgen receptor 
from seminal vesicles of rams. Cytosols containing 
analysed 
two 
distinct j 3 HjR1881-binding proteins, as 
sucrose gradient centrifugation, were incubated 
by 
with 
2' ,5'-ADP-sepharose or phosphocellulose. Only the slower 
sedimenting 3 S form appeared to be retained by 2', 5 '-ADP-
sepharose (appendix paper II) and phosphocellulose (figure 
4.3A/B), probably representing the activated steroid-
receptor complex. The fraction which did not bind to phos-
BSA 
dpm 
X 10-3 ~ 
TO 20 
bottom fractions 
A 
30 
top 
dpm 
X To-3 
bottom 
TO 20 
fractions 
B 
30 
top 
Figure 4.3: Binding of androgen receptors to phosphocellulose: 
Analysis with sucrose gradient centrifugation. 
Labelled cytosol, prepared in the presence of 50 roM molybdate 
from fresh ram seminal vesicles, was analysed with sucrose gra-
dient centrifugation (A). The same cytosol was allowed to incu-
bate with phosphocellulose for 2 h at 6°C and the fraction 
which did not bind to phosphocellulose was analysed with sucrose 
gradient centrifugation (B). Both samples (250 ~1) were layered 
on 10-30% linear sucrose gradients after treatment of the sample 
with charcoal. Non-specific binding was negligible (not shown). 
Centrifugation was performed for 210 m~n at 1 oc in a 
Beckman VTi-65 rotor at 370,000 x ga~ 
phocellulose (figure 4.3B) was stored at and 
after thawing several procedures known to activate steroid-
receptor complexes were performed with this fraction con-
taining only the 9 S sedimenting form of the receptor. 
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Figure 4.4: Activation of androgen receptors: analysis with 
sucrose gradient centrifugation. 
The fraction of the cytosol which did not bind to phosphocellu-
lose, as analysed in figure 4.3B, was subjected to several pro-
cedures known to activate steroid receptors. This "activated" 
preparation was analysed with sucrose gradient centrifugation 
(A). By subsequent incubation of this "activated" sample with 
phosphocellulose (2 h at 6°C), the fraction which did not 
bind to phosphocellulose and the fraction which could be eluted 
from phosphocellulose were analysed with sucrose gradient cen-
trifugation (B and C, respectively). 
c 
30 
top 
After incubation at 0.4 M KCl, sephadex G-25 gel filtration 
and dilution, the 9 S sedimenting form was almost completely 
converted to a 3 S sedimenting form (figure 4.4A compared to 
figure 4.4B). This fraction containing activated androgen-
receptor complexes, originating from the non-activated 9 S 
form, was incubated with phosphocellulose. This resulted in 
a complete loss of the 3 S sedimenting entity when the non-
bound fraction was analysed on sucrose gradients (figure 
4.4B), whereas still a small residue of the 
9 S peak (figure 4.4A) could be demonstrated 
already little 
(figure 4.4B). 
The part of the activated androgen-receptor complexes which 
actually was retained by phosphocellulose (figure 4.4A minus 
figure 4.4B) was eluted with KCl and sedimented ln the 3 S 
region of sucrose gradients (figure 4.4C). From these re-
sults it can be concluded that the non-activated 9 S sedi-
menting form of the androgen-receptor complex £rom ram 
seminal vesicles, can be converted into the activated 3 S 
sedimenting form. 
The receptor from cytosols from ram seminal vesicles, 
sedimenting at 3 S on 
by heating for 30 
!3 H! R1881 dissociated 
sucrose gradients, 
min at 50°C. 
could be destroyed 
The complex with 
The 
X 
apparent 
10- 1 O M. 
very slowly 
equilibrium-dissociation 
The receptor showed 
at low temperatures. 
constant (Kd) was 3. 8 
comparable relative 
affinities for androgenic steroids, whereas other steroids 
like estradiol, R5020, progesterone, diethylstilbestrol and 
triamcinolone acetonide only competed at very high con-
centrations. For further details see: appendix papers II 
and III. 
Conclusions 
The androgen-binding protein present l.n seminal 
vesicles of rams has many characteristics of the rat pros-
tate androgen receptor. Ram seminal vesicles contain 
approximately 1 pmol androgen receptors per gram of tissue. 
Because of the availability of large amounts of tissue, ram 
seminal vesicles appear to be a suitable source for large 
scale purification of androgen receptors. 
4.4 
4.4.1 
The lability of androgen receptors, probably due to 
proteolytic breakdown by enzymes in the crude cytosol frac-
tion, makes it necessary to introduce a fast and simple 
first purification step. Ammonium sulphate precipitation and 
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substituted matrices recovery ( %) purification 
of receptors factor of receptors 
from from from from 
cytoplasma nuclei cytoplasma nuclei 
heparin-sepharose 80 70 10 1 
DNA-cellulose 50 10 15 -
poly U-sepharose 70 95 15-30 5 
2'5'-ADP-sepharose 80 90 25-50 8 
carboxymethyl- 55 ND 10 ND 
sepharose 
DEAE-sephadex 45 ND 3 ND 
Table 4.1: Purification of cytoplasmic and nuclear androgen 
receptors from rat prostates. 
(ND, not determined). 
protamine sulphate precipitation with a 70% recovery and 
3-20 fold purification and 90% recovery and 10 fold purifi-
cation, respectively, were not successful despite the 
relatively high recoveries and purification factors. The 
limited success of these procedures as first purification 
steps was due to the high losses (approximately 85%) ~n the 
subsequently required steps 
desalting) prior to further 
(dissolving 
purification 
the pellet 
procedures. 
and 
These 
losses might be due partly to coprecipitation of proteo-
lytic enzymes. Therefore, we have investigated the useful-
ness of DNA-cellulose and a variety of substituted sepha-
rose columns ~n initial purification of androgen-receptor 
complexes from rat prostate. Results of recovery and 
purification of cytoplasmic and nuclear receptors are 
listed ~n table 4 .l' showing that with these column 
materials, nuclear receptors are more difficult to purify 
than cytoplasmic receptors. This is probably due to the 
more similar charges of the proteins which are present ~n 
the nuclear extracts, whereas ~n the cytosols proteins are 
present with different overall charges. In general, receptor 
samples were used after storage at -80°C, and storage at 
this temperature resulted in aggregation of receptor pro-
teins. Heparin-, 2' ,5'-ADP-, and poly U-sepharose appeared 
to be effective in deaggregating complexes for nuclear an-
drogen receptors. Results of studies with aggregated nuclear 
receptors, as analysed with sucrose gradient centrifugation, 
are shown in figure 4. SA (receptors at the bottom of the 
gradient) and analysed with agar gel electrophoresis, 
A: before 
heparin-sepharose 
dpm 
x 10-2 
15 
o~--~----~--~--~ 
bottom 
10 
fractions 
20 
top 
B: after 
heparin-sepharose 
BSA 
dpm .J,. 
X 10 ·2 
6l 
4 
2 
0 
bottom 
10 
fractions 
20 
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Figure 4.5: Sucrose gradient centrifugation of nuclear androgen 
receptors from rat prostates. 
Nuclear androgen receptors, stored at -sooc, were analysed 
with sucrose gradient centrifugation, before (A) and after (B) 
interaction with heparin-sepharose. Centrifugation was performed 
in 5-20% linear sucrose gradients, containing 0.4 M KCl, for 
18 hat 310,000 x g in a Beckman SW-60 rotor at 1°C. 
av 
are 
shown in figure 4.6A (receptors at the application site of 
the gel after electrophoresis). Interactions of receptors 
with heparin - sepharose or poly U-sepharose appeared to 
result in deaggregation of the receptors as demonstrated by 
a shift in sedimentation coefficient (figure 4.5B) and elec-
trophoretic behaviour (figure 4.6B), respectively. 
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15 
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a.s. 
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fractions 
20 
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Figure 4.6: Agar gel electrophoresis of nuclear androgen recep-
tors from rat prostates. 
Nuclear androgen receptors, stored 
with agar gel electrophoresis, before 
action with poly U-sepharose. 
at -80°C, were analysed 
(A) and after (B) inter-
2',5'-ADP-sepharose appeared to be most su~table for 
initial purification of cytoplasmic androgen receptors from 
rat prostate (table 4.1). In other experiments (Mulder et 
al., 1980) it was shown that phosphocellulose chromatography 
also gave promising results (80% recovery and 23 fold puri-
fication). 
4.4.2 
tors from ram seminal vesicles 
Based on results obtained with partial purification 
of the androgen receptors from rat prostate, experiments 
were performed to investigate whether the procedures were 
also applicable for large scale isolation of androgen 
receptors from seminal vesicles of rams. Comparable to 
results obtained with androgen receptors from rat prostate, 
DEAE-sephadex and DNA-cellulose were found to be unsuitable 
matrices for initial purification. Phosphocellulose chroma-
tography resulted in recoven.es of 90.0 ± 5.0% (±S.D., n=4) 
and 
With 
a purification factor of 10.1 
2' ,5'-ADP-sepharose somewhat 
± 4. 4% ±S.D., 
lower recoveries 
n=4). 
(70%) 
with higher purification factors (30-50 fold) were found. 
For this reason 2',5'-ADP-sepharose chromatography was 
adapted as first step in our purification procedures. To 
reduce the high costs of large scale receptor purification, 
initial procedures had to be performed with non-radio-
actively labelled steroid-receptor preparations. These 
procedures involve tissue processing followed by activation 
of receptors and 2',5'-ADP-sepharose binding. After binding 
of the receptors to 2' ,5'-ADP-sepharose, which reduced the 
volume of the receptor preparations significantly, labelling 
of receptors has been performed on the gel by exchange of 
added radioactive ligand for bound non-radioactive steroid. 
The procedure as summarized in the scheme of figure 4. 7, 
1. CYTOSOL (prepared in buffer A, containing 
50mM molybdate and 10 nM testosterone) 
2. first activation step (incubation for 30min at 6°C 
after addition of 1/5 vol. buffer A, 
containing 2M NaCI and 20nM testosterone) 
3. second activation step (dilution with 4vol. buffer A, 
containing 50nM testosterone) 
4. 2'5'-ADP-sepharose binding (for 20h at 6°C with 
30ml gel) 
5. washing procedures (with buffer A) 
6. labelling of receptors on 2'5'-ADP-sepharose (for 
60h at 6°C in buffer A, containing 1 OmM 
molybdate) 
7. washing and elution of the gel (see: figure 4. 8) 
Figure 4.7: 2',5'-ADP-sepharose chromatography of androgen 
receptors from ram seminal vesicles. 
Tissue was homogenized in 1 val buffer with a Waring blendor for 
3 x 20 s. Washing procedures (step 5) were performed on a glass 
filter, followed by more extensive washing in a Bio-Rad column. 
Labelling of receptors (step 6) was performed with 20 nM 
/3H/ DHT. Washing and elution of the gel (step 7) was 
performed as described in the legend to figure 4.8. 
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was found to be very successful. The procedure described 
involves stabilization of the androgen receptor by molybdate 
and excess non-radioactive testosterone. High concentrations 
of molybdate partly results ~n the formation of the aggre-
gated non-activated form of the receptor (figure 4.2A and 
4.3A) which does not bind to 21 ,5 1-ADP-sepharose (appendix 
paper II) and phoshocellulose (figure 4.3B). Therefore, 
additional activation steps, as described in step 2 and 
step 3 of the scheme presented in figure 4. 7. are required 
to achieve maximal binding of 
sepharose. The extensive washing 
receptors 
procedures 
to 2' ,5 1-ADP-
(step 5) are 
necessary to remove excess non-labelled testosterone and 
non-bound protein prior to incubation with J3HJ DHT (step 6). 
dpm/ml protein KCI fmol/mg protein 
X lQ-5 (mg/ml) (M) X lQ-3 
C>----0 ,._____. 
1,0 1.0 10 
0, 8 0.8 
0, 6 0.6 
0,4 0.4 
0, 2 0. 2 
Figure 4.8: Purification of androgen receptors from ram seminal 
vesicles by 2 1,5 1 -ADP-sepharose chromatography af-
ter activation of the androgen-receptor complexes. 
Activated J3HJDHT-receptor complexes, prepared from 110 g 
of tissue as described in figure 4. 7, were eluted from 30 ml 
2 1 ,5 1-ADP-sepharose with a KCl-gradient, after extensive washing 
with buffer A. Proteins were eluted with a gradient of 100 ml 
of buffer A and 100 ml of buffer A containing 1 M KCl. 10 ml 
fractions were collected from a Pharmacia column (size, 1.6 x 
20 em) and were counted for radioactivity. 
, radioactivity;o----o, protein;~ ,specific steroid 
binding activity; ----, KCl concentration. 
Results of the final washing and elution procedures are 
shown in figure 4.8. Separate peaks of protein and radio-
activity were observed. The pooled eluate fraction 
(indicated as 
I3HI DHT-receptor 
-- in 
complex 
figure 
with 
4.8) 
a 
contained 144 
specific activity 
pmol 
of 
4630 fmol/mg protein. Based on this initial procedure, 
further purification procedures involving purification and 
concentration with ammonium sulphate precipitation and 
subsequent Ultrogel ACA-44 gel chromatography have been 
established. By these procedures an almost 2,000 fold 
purification with a recovery of 33% could be obtained 
(appendix paper III). The labelled receptor was 
characterized by electrophoresis and sucrose gradient 
centrifugation (sedimentation at approximately 3 S). The 
purified receptor has a DNA binding-site and is specific 
for androgenic steroids (appendix paper III). 
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Chapter 5 
INTERACTION OF PARTIALLY PURIFIED ANDROGEN-RECEPTOR 
COMPLEXES WITH CHROMATIN 
5.1 Introduction 
The nature of the interaction and the location of 
androgen-receptor complexes on target cell chromatin, resul-
ting in ultimate gene expression, are still not known (chap-
ter 2.2.5). From experiments with rat prostatic tissue there 
are indications that the acceptor sites are located on 
internucleosomal chromatin regions (Rennie, 1979; Davies et 
al., 1980). These studies involved digestion of the chroma-
tin with nuclease after labelling the chromatin with radio-
active androgen-receptor complexes, either by incubating the 
chromatin of non-castrated rat prostates with I3HI dihydro-
testosterone in vitro or by labelling in vivo after castra-
tion and subsequent injection with 1 3 HI testosterone. 
Other s.tudies, after in vivo labelling of the chromatin 
followed by nuclease digestion, suggest that the chromatin 
acceptor sites are located in the transcriptionally active 
fraction and consist of non-histone proteins (Hiremath et 
al., 1981). A different approach to study acceptor sites on 
the chromatin involves reconstitution experiments with puri-
fied androgen-receptor complexes and isolated chromatin or 
nuclei, followed by digestion with specific nucleases and 
analysis of the fractionated chromatin by gradient centri-
fugation. In these reconstitution experiments, incubations 
have to be performed at temperatures close to 0°C. In 
addition, purified receptor preparations have to be used. 
These are important considerations, since proteolysis of 
receptors may result ~n decreased amounts of measurable 
acceptor sites and on the other hand, degradation of the 
chromatin may expose additional acceptor sites not rou-
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tinely expressed in vivo (Spelsberg et al., 1977). By using 
purified receptor preparations, the amounts of non-specific 
binding proteins that might mask acceptor sites will also 
be limited. Interaction of partially purified androgen-
receptor complexes with Sertoli cell chromatin of rat testis 
and seminal vesicle nuclei of guinea pigs has been reported 
(Tsai et al., 1980; Weinberger & Veneziale, 1980). Care has 
to be taken with respect to the salt concentration used 
during incubation. In the presence of 0.15 M KCl, binding 
of progesterone-receptor complexes was limited to the 
highest affinity class 
matin (Pikler et al., 
complexes to nuclei in 
of acceptors in chick oviduct chro-
1976). Binding of \3H\PHT-receptor 
the presence of 0.15 M KCl has been 
observed to be saturable and limited to a single class of 
acceptor sites with high affinity and limited amounts 
(Weinberger & Veneziale, 1980). Because no reports were 
available on reconstitution experiments of isolated 
androgen-receptor complexes and chromatin, followed by nu-
clease digestion and analysis of the labelled chromatin by 
gradient centrifugation, we have studied the possible inter-
action between partially purified labelled androgen-receptor 
complexes of ram seminal vesicles and rat prostates with 
chromatin of either rat prostate·, ram seminal vesicle or 
non-target tissue. 
5.2 Material and methods 
All preparative procedures were performed at 0-4°C. 
Purification of nuclei 
Procedure A procedure performed essentially as 
described by Magliozzi et al. (1971) with modifications. 
Ram seminal vesicles stored at -80°c were allowed to 
thaw on ice, and were subsequently minced with scissors and 
homogenized with a Waring Blend or in two volumes of 10 mM 
Tris-HCl (pH: 6. 7), containing 0. 25 M sucrose and 1. 5 mM 
CaC1 2 . After filtering the homogenate over two layers of 
aseptic gauze, further homogenization was performed manual-
ly in a Dounce apparatus with 35 strokes of a loose-fitting 
pestle. The homogenate was centrifuged for 15 min at 
2,000 x g and the crude nuclear pellet was resuspended in a 
solution containing, 0.44 M sucrose, 0.2 mM Pb(Ac) 2 and 0.3% 
Triton X-100 (pH: 6.5-7.0) and rehomogenized with 20 strokes 
in a Dounce apparatus. Following a further cycle of centri-
fugation, homogenization and centrifugation in a solution 
containing, 0.44 M sucrose, 1 mM MgClz and 0.3% Triton X-100 
(pH: 6.5-.7.0), the nuclear pellet was resuspended in 10 mM 
Tris-HCl buffer (pH: 6.7), containing 0.88 M sucrose and 
1. 5 mM CaC1 2 and layered on top of a discontinuous sucrose 
gradient, containing 2.2 and 1.8 M sucrose respectively, ~n 
10 mM Tris-HCl with 0.5 mM CaC1 2 (pH: 6.7). After c~ntrifu­
gation for 90 min at 95,000 x gav in a Beckman SW-27 rotor, 
the resulting nuclear pellet was washed with 10 mM Tris-HCl 
buffer (pH: 7.0), containing 0.25 M sucrose and 1 mM MgC1 2 . 
After centrifugation for 15 min at 2,000 x g the purified 
nuclei were stored at -20°C until use. 
procedure performed essentially as 
described by De Pomerai et al. (1974) with some modifi-
cations. Rat prostate 
spleen tissue (stored 
or spleen and 
at -80°C) 
ram seminal vesicle or 
was homogenized in two 
volumes of 10 mM Tris-HCl buffer (pH: 7.0), containing 0.25 
M sucrose and 1 mM CaC1 2 , either with a Waring blendor for 
2 x 30 s, or with an Ul traturrax tissue homogenizer for 
3 x 10 s, with intermediate cooling. The homogenate was fil-
tered over two layers aseptic gauze and centrifugation was 
performed for 10 min at 2,000 x g. The crude nuclear pellets 
were washed twice with 10 mM Tris-HCl buffer (pH: 7.0), con-
taining 0.25 M sucrose and 1 mM MgC1 2 and 0.2% Triton X-100, 
followed by filtration over 63 Jl gauze. The pelletted nu-
clei were subsequently resuspended ~n 10 mM Tris-HCl buffer 
( pH : 7 . 0 ) , c on t a in i n g 0 . 7 M s u c r o s e , 1 mM M g C 1 2 and 0 . 2% 
Triton X-100 and were layered on a cushion of the same 
buffer with 2.2 M sucrose. Centrifugation was performed for 
90 m~n at 95,000 x gav ~n a Beckman SW-27 rotor, and the 
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purified nuclei were washed with 10 mM Tris-HCl buffer (pH: 
7.0), containing 0.25 M sucrose, 1 mM MgC1 2 • The pellet ob-
tained after centrifugation for 10 min at 2, 000 x g was 
either stored at -20°C or used directly. 
Isolation of chromatin 
Purified nuclei were washed with 10 mM Tris-HCl 
buffer (pH: 7 .0) and after centrifugation for 10 min at 
2000 X g the nuclear pellet was resuspended in 1 mM 
Tris-HCl; pH: 6.0. Following incubation for 1 h at 0°C, 
the suspension was briefly sonicated for 3 x 3 s, with an 
Ultrasonic disintegrator (MSE, 150 watt, setting low 3), to 
ensure disruption of the swollen nuclei without gross damage 
to the chomatin structure. After centrifugation for 10 min 
at 2,000 x g the supernatant contained the chromatin. 
Incubation of chromatin with micrococcal nuclease 
-------------------------------------------------
Chromatin (1.5 mg/ml DNA as measured by light ad-
sorption at A 260 with the assumption that 22 A260 units 
correspond with 1 mg DNA) was incubated with micrococcal 
nuclease (Sigma) at 0-4 and 20 °C. The reaction 
mixture contained 5 mM Tris-HCl (pH: 8.0 at 20°C), 0.1 
mM CaC1 2 and 0.15 units micrococcal nuclease/A 260 unit. The 
reaction was stopped by the addition of EDTA (5mM final con-
centration). 
Large chromatin fragments, .after digestion with m~­
crococcal nuclease, were removed by centrifugation for 5 min 
at 15,000 x g. The supernatant (small soluble chromatin 
fragments) was centrifuged at 2°C for 16 h at 160,000 x 
gav in a Beckman SW-27 rotor through a 5-25% linear sucrose 
gradient, containing 10 mM Tris-HCl (pH: 7.0) and 2 mM EDTA. 
Fractions of 7 drops were obtained by piercing the bottom 
of the tube and the absorbance at 260 nm was monitored. 
Androgen-receptor complexes, partially purified with 
2' ,5'-ADP-sepharose and ammonium sulphate precipitation, were 
used. Purification procedures were used as described in 
chapter 4.4.1. 
Interaction of androgen-receptor complexes with chro-
matin was performed in buffer A (10 mM Tris-HCl, 1.5 mM 
EDTA, 1.5 mM dithiothreitol and 10% glycerol; pH: 7.4) with 
0.15 NaCl. Experimental procedures are described in the 
legends to the figures. 
For estimation of the amount of androgen-receptor 
complexes, protamine sulphate precipitation as described by 
Mulder et al. (1981), was used. This method involves incu-
bation of receptor preparations with 10 mM pyridoxal phos-
phate for 10 min at 0°C prior to the assay. 
Streptomycin sulphate precipitation of complexes be-
tween chromatin and the steroid-receptor complex was perfor-
med essentially as described by Webster et al. (1976). After 
incubation for 30 min at 0°C with streptomycin sulphate 
centrifugation was performed for 5 min at 5,000 x g followed 
by washing of the precipitates five times with 1 ml 0.02% 
streptomycin sulphate. 
5.3 Results 
In studies with rat prostate chromatin after diges-
tion with micrococcal nuclease 
solubility of the DNA, Rennie 
to the extent of 5% acid 
(1979) could detect only a 
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trace amount of labelled receptors not bound to chromatin. 
In that study, when nuclease digestion was continued until 
15% of the DNA was acid-soluble, the amount of receptor 
released from the chromatin was increased. This implies that 
retention of androgen-receptor complexes by chromatin ~s 
sensitive to micrococcal nuclease digestion (Rennie, 1979). 
Therefore, in studies on the interaction of androgen-recep-
tor complexes with the chromatin, mild digestion with micro-
coccal nuclease, not extending 5% acid-solubility of the DNA 
(very small DNA fragments are soluble ~n 0. 7 M perchloric 
acid at 10°C), is a prerequisite. Samples of chromatin 
from ram seminal vesicle, digested to approximately 3-5% 
acid-solubility of 
for 1 and 3 min at 
the DNA (micrococcal 
0 
20 C and 10, 20 and 
nuclease 
30 min 
digestion 
at 0-4°C) 
were analysed with sucrose gradient centrifugation. Only 
the fractions containing small DNA fragments (mainly consis-
absorbance at A260 
bottom 
I 
I 
+ 
tri-
I 
+ 
di-
11.3 5 
l 
I 
"i"\ /.t -~ 
I!~---~\ 
. \\ 
mono-nucleosome 
fractions top 
Figure 5.1: Sucrose gradient centrifugation of ram seminal 
vesicle chromatin after digestion with micrococcal 
nuclease. 
After digestion with micrococcal nuclease (0.15 units/A260 unit) 
and centrifugation for 5 min at 15,000 x g, 500 ~1 samples were 
layered on 5-25% linear sucrose gradients and centrifugation was 
performed for 16 h at 160,000 x ga in a Beckman SW-40 rotor. 
Arrow indicate position of sedimentation marker catalase 
(11.3 S). Digestion with micrococcal nuclease for, 1 min at 
20°C: --- 3 min at 20°C: 10 min at 
0-40C: -.-.- 20 min at 0-40C: · · · · · 30 min at 
o-4°c: -· ·-·. 
ting of fragments smaller than tetra-nucleosomes repre-
senting approximately 10-40% of the total DNA), were analy-
sed and the resulting profiles are shown in figure 5.1. 
Absorbence at the top of the gradient represents the very 
small DNA fragments which are soluble in perchoric acid. 
Comparable results have been obtained with rat prostate 
chromatin after micrococcal nuclease digestion (D. Breed-
veld, unpublished observations). 
In reconstitution experiments with isolated steroid-
receptor complexes and chromatin, possibly containing endo-
genous nucleases, incubations have to be performed at tempe-
ratures as close as possible to 0°C to maintain the in-
tactness of the chromatin structure. In addition, androgen-
receptor complexes are more stable at low tempe~atures. The 
conditions 
systems in 
generally used 
reconstitution 
for the various 
experiments are 
steroid-receptor 
1-2 h at 0°C 
(Mainwaring & Peterken, 1971; Klyzsejko-Stefanowicz et al., 
1976; Socher et al., 1976; Wang, The of 
13 HIR1881-receptor complexes for 
1978). 
2 h at 
stability 
0-4°C was 
studied and no significant dissociation or denaturation of 
dpm 
x 1o-3 
2 5 10 20 30 40 
[3H] R 1881-receptor complex (!JI) 
Figure 5.2: The effects of time and dilution on the stability 
of androgen-receptor complexes from ram seminal 
vesicles. 
13HIR1881-receptor complexes (0.97 fmol/~1) partially puri-
fied with 2', 5' -ADP-sepharose chromatography and ammonium sul-
phate precipitation (50% saturation), followed by desalting with 
Bio-Gel P-6DG, were used. 13HIR1881-receptor complexes were 
estimated with protamine sulphate precipitation before (open 
bars) and after incubation for 2 h at 0°C (shaded bars) in 
a final volume of 1 ml of buffer A. Values are means ± range, 
n=3. 
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the J3HJR1881-receptor complex was observed (figure 5.2). 
To investigate whether in reconstitution experiments 
androgen-receptor complexes show any interaction with iso-
lated chromatin (or fragments), 
required to separate free and 
a quantitative assay is 
chromatin-hound androgen-
receptor complexes. One procedure involved precipitation of 
the chromatin fragments together with bound steroid-receptor 
complexes by streptomycin sulphate (Webster et al., 1976). 
In studies with chick oviduct chromatin, no significant 
coprecipitation of progesterone-receptor complexes, not 
bound to chromatin, has been observed (Webster et al., 
1976). Experiments with increasing amounts of partially 
purifiec J3HIR1881-receptor comple~es from ram seminal 
vesicles, however, show that even at low concentrations of 
streptomycin sulphate (0.1 mg/ml as compared with 1.0 mg/ml 
used by Webster et al., 1976), a significant amount of 
J 3HJR1881-receptor complexes is precipitated (figure 5.3). 
dpm 
x Jo-3 
6 
.I 
Ill 
2 
0 10 20 30 40 50 
[3H] R1881-receptor complex !I'll 
Figure 5.3: Protamine sulphate prec1p1tation and streptomycin 
sulphate precipitation of androgen receptors from 
ram seminal vesicles. 
13HJR1881-receptor complexes, prepared as described in the 
iegend to figure 5.2, were used. 
~ , protamine sulphate prec1p1tation; o---o, streptomycin 
sulphate precipitation. Values are means ± range, n=3. 
At low concentrations of receptor, almost 50% of the recep-
tor precipitated with streptomycin sulphate in the absence 
of chromatin (figure 5.3). Due to the significant copreci-
pitation of androgen-receptor complexes with streptomycin 
sulphate, another procedure to separate free and chromatin-
bound steroid-receptor complexes has to be used. It was 
found to be possible to separate free and chromatin-bound 
was receptors 
evaluated 
by centrifugation at high 
with partially purified 
speed. The assay 
13 HIDHT-receptor com-
plexes and chromatin isolated from prostates of rats one day 
A B 
0.3 
0.2 
\ 
0.1 \ 
0 
\ 
\ \ \ 
\ \ 
\ \ 
0 20 40 60 80 0 20 40 0 20 40 0 20 40 
B (pM) 
Figure 5.4: Scat chard analysis of the interaction between rat 
prostate androgen-receptor complexes and chromatin. 
Increasing amounts of 13HIDHT-receptor complexes (65-720 
fmol, partially purified as described in the legend to figure 
5.2, were incubated for 90 min at 0-4°C with a fixed amount 
of chromatin (2.2 A 260 units/incubation) in 1 ml buffer A with 0.15 M NaCl. After incubation the amount of total receptors were 
estimated with protamine sulphate precipitation. The amount of 
i3HIDHT-receptor complexes bound to chromatin was estimated 
by centrifugation for 5 min at 40,000 x g and counting of the 
pellet after one (A), two (B), three (C) or four (D) washing 
steps with 1 ml buffer A followed by centrifugation for 5 min at 
40,000 X g. 
C: B rn 
D: B rn 
19 pM; Kd 
20 pM; Kd 
0.88 X 10-lOM. 
o.86 x 1o-1oM. 
77 
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after castration. Although it seems that there is a single 
class of acceptor sites after one and two washing steps 
(figure 5.4 A/B), this probably reflects experimental arti-
facts due to non-specific binding of free \3H\ DHT-receptor 
complexes to chromatin or to the wall of the assay tube. Due 
to the limited range of \3H\DHT-receptor complexes, used 
these low affinity binding sites, however, could not be 
demonstrated in the figures 5.4 A/B. After the third and 
fou~th washing step, the non-specifically bound \3H\DHT 
receptor complexes are released because the dissociation 
constant (Kd: 0.88 and 0.86 x 10- 10 M, respectively) and the 
amount of acceptor sites (0.19 and 0.20 pmol/mg DNA, respec-
B 
15 • 15 
10 10 
5 5 
0~---------,------~--r---- 04---------r---~---r--
0 5 10 0 5 10 
B (pM) B (pM) 
Figure 5.5: Scatchard analysis of the interaction between 
androgen-receptor complexes from ram seminal vesi-
cles and chromatin of prostate (A) and spleen (B) 
of castrated rats. 
Increasing amounts of \3H\DHT-receptor complexes (15-810 
fmol) were incubated for 90 min at 0-4°C with a fixed 
amount of chromatin (1.6 A260 units/incubation) in 1 ml buffer A with 0.15 M NaCl. The amount of total and chromatin-bound the 
androgen-receptor comp).exes were estimated after four washing 
steps as described in the legend to figure 5.4. 
A: Bm 
B: Bm 
9.1 pM; Kd: o. 73 X 10-9M. 
8.3 pM; Kd: 0.77 X 10-9M. 
tively) remained apparently similar (figure 5.4 C/D). The 
estimated dissociation constant appears to be essentially 
the same as has been found for the interaction between 
androgen-receptor complexes and chromatin from guinea pig 
seminal visicles 0.83 X l0- 10 M; Weinberger & 
Veneziale, 1980). In heterologous reconstitution experiments 
with partially purified androgen-receptor complexes from ram 
seminal vesicles and chromatin from prostate and spleen of 
rats one day after castration (figure 5.5 A/B), dissociation 
constants 
X 10- 9 M 
were 
and 
found 
Kd: 
to be a 
0,77 X 
factor 10 higher (Kd: 0. 7 3 
10- 9 M, respectively), than 
observed for the homologous reconstitution experiments as 
described ~n figure 5.4. The estimated amounts of chromatin 
acceptor sites were of the same order of magnitude (0.13 and 
0.12 pmol/mg DNA for prostate and spleen respectively, as 
compared to 0.20 pmol/mg DNA in the experiments described 
in figure 5 • 4 • ) • 
5.4 Discussion and conclusion 
For the assay of androgen-receptor complexes bound 
to chromatin, high speed centrifugation appeared to be 
superior over streptomycin sulphate precipitation. 
In preliminary reconstitution experiments ~s was 
demonstrated that isolated androgen-receptor complexes show 
high affinity interaction with isolated chromatin. In homo-
logous reconstitution experiments with receptor and chroma-
tin from rat prostate, the estimated dissociation constant 
appeared to be a factor 10 lower than ~n heterologous recon-
stitution experiments with androgen-receptor complexes iso-
lated from ram seminal vesicles and chromatin of prostate 
and spleen of castrated rats. No tissue specifity was 
observed. These results may reflect binding to regions of 
the DNA, which become exposed as a result of some disruption 
of the chromatin by the mild sonication procedure, necessary 
for lysis of the nuclei. The limited 
sites/nucleus) of high affinity sites 
amounts 1,000-1,500 
X 10- 10 M), 
however, which remain constant after three washing steps may 
79 
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be indications of a specific process (figure 5.4). In addi-
tion, the observed saturable binding of the progesterone 
receptor to DNA containing limited nicks which becomes non-
saturable as nicks were increased (Hughes et al., 1981), are 
~n favor with the assumption that there was no gross damage 
of the chromatin, as a result of the isolation procedure or 
the presence of nucleases, ~n our experiments. It remains to 
be established, however, whether the interaction observed in 
heterologous reconstitution experiments (figure 5.5 A/B) 
really reflects binding of the androgen-receptor complexes 
to chromatin acceptor sites. In this respect control experi-
ments involving interaction of isolated androgen-receptor 
complexes with purified nuclei, probably containing intact 
chromatin, have to be performed. 
Homologous reconstitution experiments with ram semi-
nal vesicle 
sofar, due 
receptor and 
to the lack of 
chromatin were 
availability of 
not successful 
chromatin with 
unoccupied acceptor sites. Therefore, ram seminal vesicles 
have to be isolated from castrated rams 
whether dissociation constants and binding 
to investigate 
capacities are 
such experiments 
chromatin inter-
comparable to the rat prostate system. In 
it should also be possible to evaluate the 
action of androgen-receptor complexes 
heterologous reconstitution experiments, 
with chromatin in 
which apparently 
show no tissue-specificity. 
In conclusion, the preliminary experiments described 
appear promising, because the results have shown that the 
purified androgen-receptor complexes still possess their 
chromatin-binding sites. In future reconstitution experi-
ments the location of chromatin-acceptor sites, when shown 
to be specific, should be studied with controlled nuclease 
digestion and sucrose gradient centrifugation analysis of 
the released fragments. 
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Chapter 6 
GENERAL DISCUSSION 
tatic diseases 
A possitive correlation exists between estrogen re-
ceptor content and the response to endocrine therapy of 
human breast cancers (Jensen, 1981). It appeared reasonable 
to suggest that in analogy with breast cancer a correlation 
could exist between the androgen receptor content and the 
benefit form endocrine management of human prostatic di-
seases. In 75-80% of all prostatic carcinomas the growth of 
the tumor can be controlled by hormonal manipulations 
(Fergusson, 1972). It is possible that the prostate tissue 
of the remaining 20-25% of the patients not responding to 
endocrine therapy have low androgen receptor levels or no 
receptors et all. For this reason a reliable androgen 
receptor assay has to be available for clinical purposes. 
With a reliable assay it might be possible to select 
patients which could benefit from the appropiate therapy. 
As has been discussed ~n chapter 3.1.4, controversial re-
sults have been reported concerning the correlation between 
androgen receptor content and the response to endocrine 
treatment (Wagner & Schultz, 1978; Ekman et al., 1979). 
These studies, however, involved the measurement of cyto-
plasmic receptors and, as has been discussed in chapter 
3. 1. 2' the accurate estimation of androgen receptors ~n 
cytosol fractions of human prostatic tissue is associated 
with many problems. The predominantly nuclear localization 
of androgen receptors ~n these tissues (Sirett & Grant, 
1978; Hicks & Walsh, 1 9 7 9) and the fact that androgens 
exert their major influence within the nucleus of target 
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cells (chapter 2), suggest that the measurement of nuclear 
receptors may be more valuable. The applicability of the 
assay developed (appendix paper I) for nuclear androgen re-
ceptors for biopsy-size specimens has been investigated 
(Blankenstein et al., 1982). With this method, it was found 
that nuclear androgen receptors can be measured ~n as little 
as 25 mg of tissue. At present no reports have appeared ~n 
the literature dealing with nuclear androgen receptor levels 
and the response to endocrine therapy. For this reason it 
remains to be established whether nuclear androgen receptor 
levels will show useful correlations with the clinical 
response to endocrine management. The methodology for this 
study is now available. 
For further study of the mechanism of action of an-
drogens, purification of androgen receptors ~s of extreme 
importance (chapter 4.4.1). However, several serious pro-
blems are associated with the purification of androgen 
receptor proteins, e.g. the extreme lability of androgen-
receptor complexes and the small amount of androgen recep-
tors present ~n androgen target tissues. In addition, these 
tissues contain high amounts of proteolytic enzymes which 
resist commonly used inhibitors, such as PMSF (Mainwaring, 
1978). Another difficulty involves the requirement of radio-
active androgen-receptor complexes which is necessary to 
follow the receptor proteins during the purification proce-
dures. Purification methods should therefore, also cons~­
dering the extreme lability of androgen receptors, be rapid 
to prevent dissociation and denaturation of the androgen-
receptor complexes. Despite these drawbacks, which have 
been discussed ~n more detail ~n chapter 4.1.1., we have 
concentrated our efforts 
androgen receptors, with 
on 
the 
the 
goal 
purification of 
to provide more 
these 
in for-
mat ion on the mechanism of action of androgens. Future pros-
research with purified androgen-
a is cussed in chapter 6 . 4 . The 
pects of androgen-receptor 
receptor complexes will be 
small size of rat prostates makes this tissue unattractive 
for isolation of androgen receptors at a large scale. It has 
been demonstrated, however, that seminal vesicles of rams 
contain both nuclear and cytoplasmic androgen receptors 
(chapter 4.3 and appendix paper II). These androgen recep-
tors showed characteristics comparable to the androgen re-
ceptors of rat prostate. The amount of receptors present 
(approximately 1 pmol per gram of tissue) and the availa-
bility of the tissue, which can be easily obtained from the 
slaughterhouse, make ram seminal vesicle tissue very attrac-
tive as a source for large scale isolation of androgen 
receptors. For stabilization of the labile androgen receptor 
proteins, molybdate, which has also been shown to stabilize 
androgen receptors from rat prostate (Gaubert et al., 1980), 
had to be included ~n our experiments (chapter 4.3 and 
appendix paper II). Purification of these androgen receptors 
with affinity chromatography is essentially useless, because 
this method which involves matrices containing immobilized 
steroids, requires that the receptor has to be presented to 
the matrix in its onuccupied form. In ram seminal vesicles, 
obtained from non-castrated animals, however, most receptors 
are coupled with endogeneous androgens. Moreover, notwith-
standing the successes obtained with affinity chromatography 
~n the purification of several steroid receptors, this 
method has not been successful for the isolation of androgen 
receptors from castrated rats (discussed in chapter 4.1.2). 
In addition, ~n recent studies, affinity chromatography is 
not used for large scale purification of progesterone and 
glucocorticoid receptors (Payvar et al., 1981; Weigel et 
al., 1981). We have investigated several procedures for 
protein fractionation which involve mainly affinity for the 
DNA-site of the receptor (chapter 4.4.2). In these studies, 
advantage was taken by the fact that steroid receptors 
possess a common feature, i.e. binding to DNA-like matrices 
when the receptors are ~n their activated form (chapter 
2.2.3 and 4.3). However, molybdate, which appeared to be 
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.essential for stabilization of receptors, also inhibits the 
transformation of and ro gen-re ce p tor camp lexes to their ac-
tivated form. This problem has been solved by carefully 
selecting conditions that sufficiently stabilize the recep-
tor followed by procedures which provoke activation of the 
androgen-receptor complexes (induced by high salt concen-
trations, 
sepharose 
cation of 
figure 4.7). From 
appeared to be most 
androgen-receptor 
the gels 
suitable 
complexes 
tested, 2', 5 '-ADP-
for initial purifi-
(chapter 4.4.1 and 
4.4.2). Further purification procedures have been investi-
gated and it has been established that an almost two thou-
sand fold purified receptor preparation could be obtained 
with an overall recovery of approximately 30%. These pro-
cedures involved 2', 5' -ADP-sepharose chromatography, ammo-
nium sulphate precipitation and gel chromatography on Ultra-
gel ACA-44. Further details of these procedures have been 
described 1n chapter 4.4.2 and appendix paper III. The 
purified cytoplasmic receptor, which still possesses its DNA 
binding site, showed characteristics comparable to the 
androgen receptor isolated from the cytoplasm of rat pros-
tates, as shown by analysis with agar gel electrophoresis 
and sucrose gradient centrifugation (appendix paper III). 
Further purification of this partially purified receptor 
might be accomplished by the procedure as described very 
recently by Bruchovsky and associates. This method, which 
has been found to be successful for a 100 fold purification 
of the nuclear androgen-receptor complex from rat prostates, 
involves hydrophobic interaction chromatography with w-alkyl 
derivatives coupled to agarose (Bruchovsky et al., 1981). In 
addition, as a first purification step, the procedure des-
cribed for the progesterone receptor by Weigel et al., 
(1981) might also be very worthwile. This procedure involved 
chromatography of the untreated cytosol on a DNA-cellulose 
column, resulting 1n a "flow-through" fraction containing 
proteins, including the non-activated receptor, which do not 
interact with DNA-cellulose, whereas the DNA-binding pro-
teins were selectively retained by the column. Subsequently 
the non-activated receptors 1n the "flow-through" fraction 
were chromatographed on a phosphocellulose column after an 
activation process of the receptor. 
6. 3. 
isolated chromatin 
Experiments described in chapter 5.3 were performed 
to gain information about nuclear acceptor sites for andro-
gen receptors on the chromatin. The reconstitution experi-
ments with partially purified androgen-receptor complexes 
and isolated chromatin are still preliminary. The techniques 
described in chapter 5.3, however, for micrococcal nuclease· 
digestion of the chromatin and h£gh affinity binding of iso-
lated androgen-receptor complexes with chromatin make it now 
possible to start experiments on tissue specificity via 
homologous and heterologous reconstitution experiments. 
After binding of androgen-receptor complexes to the chroma-
tin a variety of experiments can be performed using diffe-
rent nucleases for specific digestion of the chromatin. 
Following digestion and analysis of chromatin fragments by 
sucrose gradient centrifugation before and after selective 
removal of various chromatin components, information may be 
obtained about the nature and localization of chromatin 
acceptor sites. With highly purified receptor preparations, 
experimental artifacts will probably be minimized (chapters 
5.1. and 5.4). For these reconstruction experiments, there-
fore, the use of highly purified receptor preparations, pre-
pared as described in chapter 4.4.2 and appendix paper III, 
not containing nucleases~). is required. 
~)Recently Dr. M. Parker (Imp. Cancer Res. Fund. London), 
using a very sensitive assay, showed that these highly 
purified preparations are free o£ nucleases. The assay 
involved incubation of the receptor preparations with 
circular DNA, followed by analysis on gels. 
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During the past fifteen years, s~nce radioactively 
labelled androgens became available as marker for the recep-
tor protein to which it binds, it has been possible to study 
androgen receptor interactions. The overall pattern of 
androgen receptor interactions ~s reasonably clear, but de-
tailed understanding of the processes of receptor-synthesis, 
-activation, -translocation, -binding to the nucleus and 
-replenishment is still far from complete. Procedures for 
characterization and purification of the extremely labile 
androgen-receptor complex are rather time consuming. Hence, 
to prevent dissociation of the androgen-receptor complex, it 
would be desirable to possess a receptor preparation with a 
labelled steroid covalently linked to the steroid binding 
site of the receptor. Covalent coupling has been success-
fully performed with the subunits A and B of the proges-
terone receptor by photoaffinity labelling ~n vitro with 
the synthetic progesterone R5020 (Schrader et al., 1980). 
The same method tested for coupling of the synthetic andro-
gen Rl881 to the androgen receptor has not been successful 
thus far (Mulder & Vrij, 1981; Rennie, 1981). Recently, how-
ever, Mainwaring & Johnson (1980) succeeded ~n covalent 
coupling of a steroid to the androgen receptor by affinity 
labelling with J 14 cl-17~-bromoacetoxy testosterone. 
With this affinity labelled receptor from rat prostate and 
based on the procedure as described for the purification of 
the estradiol receptor (Molinari et al., 1977), Mainwa-cing 
& Johnson (1980) described priliminary results of a 50,000 
fold purification of the androgen receptor. It has to be 
established, however, whether this purified receptor 
associated with the affinity label can be translocated into 
nuclei in a reconstituted cell-free system. Until it has 
been achieved that purified androgen receptor covalently 
coupled with a radioactive steroid, which also translocate 
into nuclei in reconstituted cell-free system, are avail-
able, reconstitution experiments have to be performed with 
labile androgen-receptor complexes. Reconstitution experi-
ments might involve the approach which has been discussed 
1n chapter 6.3, with the ultimate goal to gain 
nature and localization of the more information about the 
chromatin 
chroma ti-n 
acceptor 
acceptor 
sites. Another 
sites might be 
approach 
to try to 
for studying 
exchange the 
steroid of the chromatin bound androgen-receptor 
for added radioactive androgens, after isolation 
or chromatin from tissue of non-castrated animals. 
complexes 
of nuclei 
The main 
disadvantage of this procedure will be the time required for 
exchanging the steroid. Long incubation times (20 h at 10°C) 
1n vitro, may cause changes Gf the native conformation of 
the chromatin which might result 1n experimental artifacts. 
It has been concluded that steroid hormone-receptor 
complexes increase rapidly and selectively the rate at which 
specific transcripts are synthesized. In cultured host 
cells, bearing integrated mouse mammary tumor virus genes 
(MMTV-genes) introduced by infection, glucocorticoid hor-
mones specifically stimulate the rate of viral gene trans-
cription in a hormonal dependent manner (Ringold et al., 
1977; Grove et al., 1980; Lee et al., 1981). Possible speci-
fic interaction of steroid-receptor complexes with naked DNA 
has been dicussed (chapter 2.2.5). In addition, it has been 
reported very recently 
tors bind selectively 
that purified glucocorticoid recep-
in vitro to a cloned DNA fragment 
(MMTV-DNA) 
ticoids in 
interaction 
cloned DNA 
whose 
vivo 
transcription 
(Payvar et al., 
is regulated by glucocor-
1981). Possible specific 
of purified androgen-receptor complexes with 
fragments might give information about the 
function of androgen receptors in gene 
complementary to three androgen-dependent 
regulation. 
mRNAs from 
DNA, 
rat 
ventral prostate (cDNAs) has been cloned in the bacterial 
plasmid pAT153 (Parker et al., 1980). These androgen-
dependent mRNAs code for the expression of three polypep-
tides (subunits of prostatic binding protein (PEP)). These 
polypeptides, representing about 50% of the total protein 
synthesized in the rat ventral prostate (Heyns et al., 
1977; Parker et al., 1978), are secreted by this tissue. 
The specific recognition site for androgen-receptor com-
plexes will probably be located upstream the gene which con-
tains the information for prostatic binding protein. With the 
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cloned cDNAs it might be possible to isolate the original 
genes which code for PBP, together with its flanking genes. 
With these probes, binding experiments could be performed 
binding site with highly purified receptors. A specific 
might be isolated by selective digestion of the DNA by spe-
cific restriction enzymes. In addition, studies on gene 
regulation by androgens could be performed with an androgen-
dependent cell-line in an approach similar as has been des-
crib ed for the glucocorticoid receptor system (Coffini, 
1981). Shionogi mammary carcinoma cells, e.g., which are 
subdivided into androgen-dependent and autonomous cells 
(King et al., 1976; Bruchovsky & Rennie, 1978) and which 
originally not synthesize PBP, might be used. After inser-
ting genes coding for PBP, connected with its flanking 
genes, in the genome of the Shionogi cells, possible expres-
sion of these genes on androgen administration might be qb-
served. By specific alteration of the flanking genes before 
inserting them in the host genome, valuable information on 
regulation 
available. 
of gene expression by androgens may become 
Further investigation of the mechanism of action of 
androgens at the molecular level req-uires methods to 
recognize the receptor protein that do not depend on its 
binding to labelled androgens. One possible approach is the 
use of specific antibodies against the receptor itself. 
Antibodies have been raised against the estradiol receptor 
of calf uterine nuclei (Greene et al., 1980a; Jensen et 
al., 1980), of human breast cancer cytosol (Greene et 
1980b), against the glucocorticoid receptor of 
al., 
rat 
liver cytosol (Govindan, 1979; Eisen, 1980) and against the 
progesterone receptor from rabbit uterine cytosol (Logeat et 
al., 1981). If such antibodies would also be available for 
the androgen receptor, this would permit the application of 
immunochemical techniques for the detection of receptors, 
and such antibodies would therefore offer great promises as 
reagents for the elucidation of the mechanism of action of 
androgens at the molecular level. Another important paten-
tial application of antibodies against the receptor might 
be immunoradiographical analysis of androgen receptors ~n 
prostatic cancer tissue as a guide to therapy. To raise 
antibodies via the monoclonal antibody technique, purified 
receptor preparations, prepared as described in appendix 
paper III, may be used. 
In conclusion, fruitful further studies in androgen-
receptor research involve the complete purification of an-
drogen receptors, covalent binding of steroid to the recep-
tor, monoclonal antibodies to the receptor and in the end a 
model system in which the regulation of androgen-dependent 
genes by androgen receptors can be studied in detail. 
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SUMMARY 
Interaction of a steroid hormone with specific re-
ceptor proteins with high affinity, is one of the first 
events occuring in target organs of that specific hormone. 
After various as yet ill-understood processes in the cyto-
plasm, the steroid-receptor complex migrates to the nucleus, 
which ultimately results ~n the observed effects on the tar-
get cell. 
It has been described that human breast tumors can be 
treated with about 50% more success with endocrine therapy 
if the tissue contains the specific receptor protein for the 
female steroid hormone estradiol. Steroid-receptor complexes 
exert their action ~n the nucleus and the high endogeneous 
levels of androgP.ns ~n human prostatic tissue result ~n a 
predominantly nuclear 
would appear logical 
localization of receptors. Hence, it 
to measure androgen receptors in nuclei 
of 
The 
human prostatic tissues 
experiments described 
as a possible guide to therapy. 
in the first part of this thesis 
were performed with the goal to develop a reliable assay for 
nuclear receptors for androgens in the human prostate. In 
further 
ceptors 
detailed 
experiments purification procedures 
were studied with the ultimate goal 
information on the mechanism of 
for androgen re-
to achieve more 
action of andro-
gens. Particularly to investigate nature and subnuclear lo-
calization of the acceptor site(s) on the chromatin ("Scope 
of this thesis", chapter 1). 
The literature, dealing with the known and unknown 
biochemical processes which can play a role in the effects 
of steroid hormones, has been discussed in chapter 2. 
Chapter 3.1 describes the various assays which have 
been developed to estimate the amount of androgen receptors 
~n human prostatic 
l.n the literature 
tissue together with the results reported 
concerning both cytoplasmic and nuclear 
receptors. Especially drawbacks ~n estimating cytoplasmic 
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androgen receptors ~n human prostatic tissues and the prog-
nostic value ~n estimation of androgen receptors ~n endo-
cr~ne treatment of :'rostatic diseases have been discussed. 
On account of the many methodological difficulties in measu-
ring cytoplasmic receptors in human prostatic tissues and 
because most receptors are expected in the nucleus, an assay 
for nuclear receptors in benign prostatic hyperplastic 
tissue was developed. Results are described in appendix 
paper I. In the method described, the commonly used extrac-
tion of nuclei is modified. Instead of extracting with a 
buffer containing 0.4 M KCl, extraction is performed with a 
buffer with heparin. As a result, the amount of receptors 
found was approximately two times higher than the values 
found after KCl extraction. Additionally, heparin stabilizes 
the steroid-receptor complex. 
To gain more insight in the mechanism of action of 
steroid hormones it is of importance to have a purified 
receptor preparation. In chapter 4.1 the purification of 
steroid receptors in general ~s discussed on basis of re-
sults from the literature. Due to very low amounts of 
androgen receptors ~n their target cells (approximately 
10 Jlg ~n thousand rat prostates) it is not practical to 
isolate the receptors from rat prostate tissue at a large 
scale. It was investigated whether seminal vesicles of the 
ram, which can be obtained from the slaughterhouse in large 
amounts, would be a sui table source for large scale purifi-
cation of androgen receptors. In chapters 4.2-4.4 and appen-
dix papers II and III experiments are described concernirg 
characterization and purification of androgen receptors from 
ram seminal vesicles. It appears that this tissue contained 
almost the same concentration of androgen receptors as rat 
prostate tissue. It was concluded that ram seminal vesicles 
tissue is a very suitable source for isolation of androgen 
receptors. With sucrose gradient centrifugation two forms 
on the unpurified receptor were characterized, one sedimen-
ting at 9 Sand one sedimenting at 3 S. These forms of the 
receptor have been found also ~n cytosols of rat prostates. 
In chapter 4.4. various purification procedures have been 
described, showing that 2', 5 '-ADP-sepharose chromatography 
is most suitable as a 
purification procedures 
fold purified receptor 
appendix paper III. 
first purification step. Further 
which resulted in a two thousand 
are described in chapter 4.4.1 and 
Interaction of steroid-receptor complexes with chro-
matin, as described in the literature, is discussed ~n chap-
ters 2.2.5 and 5.1. Controversial results have been reported 
with respect to the amounts and localization of acceptor 
sites ~n the chromatin. Preliminary experiments with puri-
fied androgen-receptor complexes from rat prostates and ram 
seminal vesicles and isolated chromatin are described in 
chapters 5.2-5.4. High affinity interaction of androgen-
receptor complexes with chromatin was observed. 
A "general discussion" is presented in chapter 6. The 
usefulness of a nuclear androgen receptor assay for human 
prostatic tissue together with future prospects of androgen-
receptor research are described. 
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SAMENVATTING 
De interaktie van steroid-hormonen met specifieke 
receptor-eiwitten, welke het hormoon met hoge affiniteit 
bind en, 
den in 
is een van de eerste gebeurtenissen die plaats vin-
de zogenaamde doelwitorganen voor dat specifieke 
steroid-hormoon. Als gevolg hiervan worden diverse complexe 
processen beinvloed, hetgeen uiteindelijk resulteert in een 
toename van de synthese van specifieke eiwitten. 
In de literatuur is beschreven, dat endocriene thera-
pie van humane mamma tumoren een twee maal zo grote kans op 
succes heeft indien het weefsel het specifieke receptor-
eiwit bevat voor het vrouwelijke steroid-hormoon oestradiol. 
Hieruit blijkt dat het van groot belang kan zijn om het 
receptor-eiwit in dergelijke maligne tumoren te kunnen meten 
alvorens tot therapie over te gaan. De laatste jaren wordt 
intensief onderzocht of naar analogie van 
een dergelijke korrelatie ook bestaat bij 
de mammatumoren 
de humane pros-
taattumoren wat betreft de aanwezigheid van receptoren voor 
androgenen (mannelijk steroid-hormoon) en de respons op 
endocriene therapie. Hiervoor is het van essentieel belang 
dat er een betrouwbare receptor bepaling beschikbaar lS. 
Volgens het nu algemeen aanvaarde werkingsmechanisme van 
steroid-hormonen oefent het mannelijk steroid testosteronen 
zijn werking uit op doelwitweefsels door binding aan een 
cytoplasmatisch receptor-eiwit, nadat het steroid is omgezet 
tot dihydrotestosteron. In aansluiting op diverse nog niet 
volledig begrepen processen in het cytoplasma wordt het 
steroid-receptor complex in de celkern gebonden aan acceptor 
plaatsen op de chromatine, hetgeen uiteindelijk leidt tot 
het waargenomen effekt van het hormoon op de doelwitcel. De 
werking van het steroid-r~ceptor complex vindt plaats in de 
kern en het ligt dan ook voor de hand om de hoeveelheid an-
drogeen receptoren in humane prostaatweefsels te meten in 
de kern, ook al omdat men de meeste receptoren ln de kern 
kan verwachten vanwege het hoge endogene androgeen gehalte. 
De ln het eerste gedeelte van dit proefschrift be-
schreven experimenten werden uitgevoerd met het doel om een 
goede methode te ontwikkelen voor de bepaling van androgeen 
receptoren in de kernfraktie van humane prostaatweefsels. In 
andere experimenten werden methoden voor de zuivering van 
androgeen-receptoren onderzocht met het uiteindelijke doel 
om meer gedetailleerde gegevens te verkrijgen over het wer-
kingsmechanisme 
verde receptor 
van androgenen en 
preparaten de aard 
torplaats(en) op het chromatine 
this thesis", hoofstuk 1). 
vooral ook om met gezui-
en 
te 
lokatie van 
onderzoeken 
de accep-
("Scope of 
Een literatuuronderzoek, handelend over de tot nu toe 
bekend geachte processen welke een rol spelen in hormonale 
effekten vanaf de interaktie met zijn cytoplasmatische re-
ceptor tot de uiteindelijke gen-expressie, is weergegeven 
in hoofdstuk 2. 
In hoofdstuk 3.1 is een literatuuroverzicht gegeven 
van de diverse bepalingsmethoden voor androgeen receptoren 
1.n humane prostaatweefsels alsmede van de resultaten die 
verkregen zijn voor zowel de cytoplasmatische als voor de 
kern receptoren. Ingegaan wordt op de vele bezwaren die er 
zijn tegen het meten van deze receptoren in het cytoplasma. 
De prognotische betekenis van het meten van androgeen recep-
toren bij de endocriene behandeling van ziekten van de pros-
taat wordt besproken. Op grond van de methodologische bezwa-
ren tegen het bepalen in humane prostaatweefsels van cyto-
plasmatische androgeen-receptoren en vanwege de verwachting 
dat de meeste receptoren in de kern ge1okaliseerd zijn, werd 
een methode ontwikkeld voor de bepaling van receptoren 1.n 
kernen van benigne hyperplastisch prostaatweefsel. De resul-
taten zijn beschreven in appendix- publikatie I. In de 
methode die wordt beschreven is onder andere de tot nu toe 
gebruikte extraktie van kernen gemodificeerd; in plaats van 
met 0.4 M KCl wordt geextraheerd met een buffer welke hepa-
rine bevat. Dit heeft als resultaat dat de gemeten receptor 
concentraties ongeveer twee maal hoger zijn dan na de 
extractie met KCl. Bovendien werkt het heparine stabilise-
rend op het steroid-receptor complex. 
Om een beter inzicht te verkrijgen in het werkings-
mechanisme van steroid-hormonen is het van belang om over 
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een gezuiverd receptor preparaat te beschikken. In hoofdstuk 
4.1 is een literatuuroverzicht gegeven van de tot op heden 
beschreven resu1taten welke behaald zijn bij de zuivering 
van steroid receptoren in het algemeen. Aangezien androgeen 
receptoren J.n zeer geringe hoeveelheden voorkomen in hun 
doelwitorganen (ca. 10 microgram in 1000 ratte-prostaten), 
is het niet goed mogelijk deze receptoren op grote sc,haal 
te isoleren uit ratteprostaat. Onderzocht werd of ~aadb1azen 
van de ram, welke in grote hoeveelheden via het s1achthuis 
verkrijgbaar zijn, een geschikt weefsel vormen voor zuive-
ring van deze receptoren op grote schaal. In de hoofdstukken 
4.2-4.4 en appendix-publikaties II en III zijn experimenten 
beschreven over de karakterisering en gedeeltelijke zuive-
ring van de androgeen receptor van de zaadblaas van de ram. 
Het bleek dat de concentraties van de androgeen-receptoren 
in dit weefsel ongeveer even hoog waren als in de rattepros-
taat en er is gekonkludeerd dat dit weefsel een zeer ge-
schikte bron is voor isolatie van de receptor. Op sucrose 
gradienten worden in het cytoplasma van de zaadblaas twee 
vormen van de ongezuiverde androgeen receptor gevonden, 
n.l. een die sedimenteert als een 9 s- en een als een 
3 S-verbinding. Deze vormen van de cytoplasmatische receptor 
worden ook gevonden in het cytoplasma van de prostaat van de 
rat. In hoofdstuk 4.4 zijn diverse zuiveringsmethoden be-
schreven waaruit blijkt dat het gebruik van 2' ,5'-ADP-
sepharose vooralsnog het meest geschikt lijkt te zijn als 
eerste stap bij de zuivering van de androgeen receptor. De 
daaropvolgende zuiveringsstappen om te komen tot een twee-
duizendmaal gezuiverd preparaat zijn beschreven in hoofdstuk 
4.4.1 en appendix publikatie III. 
In de hoofdstukken 2.2.5 en 5.1 is een literatuur-
overzicht gegeven van studies welke handelen over de inter-
aktie van steroid-hormoon-receptor complexen met chromatine. 
De verschenen publikaties zijn zeer tegenstrijdig wat 
betreft het aantal en de lokatie van de acceptor plaatsen 
op het chromatine. Om meer duidelijkheid te verschaffen over 
de werkelijke hoeveelheden en lokatie van de chromatine bin-
dingsplaatsen zijn experimenten uitgevoerd met 6edeeltelijk 
gezuiverde androgeen-receptor complexen van ratteprostaat 
en zaadblazen van de ram met hun respektievelijke geiso-
leerde chromatines (hoo fdstukken 5.2-5.4). Er werden 
interakties met hoge affiniteit waargenomen tussen de 
androgeen-receptor complexen en het chromatine (voorlopige 
experimenten). 
In de "General discussion" (hoofdstuk 6) zijn de 
verkregen resultaten besproken aan de hand van gegevens 
welke in de literatuur vermeld zijn. De toepassing van de 
ontwikkelde methode voor de bepaling van kern receptoren bij 
de endocriene behandeling van ziekten van de prostaat kan 
van belang zijn en wordt besproken in hoofdstuk 6.1. De re-
sultaten, verkregen bij de zuivering en karakterisering van 
de androgeen-receptor uit de zaadblaas van de ram en de 
studies die uitgevoerd zijn met deze gedeeltelijk gezuiverde 
receptor en geisoleerde chromatine, worden besproken in het 
licht van de mogelijkheden voor verder onderzoek. 
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NON STANDARD ABBREVIATIONS AND TRIVIAL NAMES 
BPH 
dihydrotestosterone 
estradiol 
methyltrienolone 
PMSF 
progesterone 
R5020 
SHBG 
testosterone 
triamcinolone acetonide 
- benign prostatic hyperplasia 
- 17S-hydroxy-5a-androstane-3-
one (DHT) 
- 1,3,5-(10)-estratriene-3,17S-
diol 
- 17S-hydroxy-17a-methyl-4,9,11-
estratriene-3-one (R1881) 
- phenylmelthylsulphonylfluoride 
- 4-pregnane-3,20-dione 
- 17,21-dimethyl-19-norpregna-4, 
9-diene-3,20-dione 
- sex hormone binding globulin 
- 17S-hydroxy-4-androsten-3-one 
- 9a-fluoro-11S,21-dihydroxy-16a, 
17-iso-propylidenedioxy-1,4-
pregnadiene-3,20-dione 
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Summary 
A procedure for the estimation of nuclear androgen receptors in benign 
prostatic hyperplastic tissue is described, which employs extraction of recep-
tors from nuclei with buffers containing heparin. Extraction of a nuclear pellet 
with a heparin-containing (1 g/l) buffer appeared to have definite advantages 
over 0.4 mol/1 KCl extraction. Heparin appeared to be twice as efficient in 
extracting androgen receptors. In addition aggregated receptor proteins, formed 
after storage at -80° C, were partly deaggregated by heparin. Specific isolation 
of the androgen receptor was performed using either agar gel electrophoresis, 
protamine sulphate precipitation or LH-20 gel filtration. A comparison was 
made between the amounts of estimated receptors with these different tech-
niques. Protamine sulphate precipitation resulted in the highest estimates of 
receptor-bound 5a-[ 3H]dihydrotestosterone CH-DHT). Treatment of the 
labelled nuclear extracts with a charcoal suspension prior to the receptor assay 
resulted in lower amounts of estimated androgen receptors. A method for 
routine evaluation of nuclear androgen receptors in prostatic tissue has been 
evaluated, which involves extraction of nuclear pellets with a heparin-contain-
ing (1 g/l) buffer, exchange labelling of the nuclear extracts for 20 h at 10°C 
and quantification of the receptors with protamine sulphate precipitation. 
Introduction 
The prostate is a target organ for androgens and does not develop in the 
absence of androgens. Androgens play a role in hyperplasia and cancer of the 
* Correspondence to: J.A. Foekens, Department of Biochemistry II, Medical Faculty, Erasmus Univer-
sity Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. 
Abbreviation used: methyltrienolone (R 1881), 17/3-hydroxy-17oc-methyl·estra-4,9,11-trien·3-one. 
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human prostate, because after castration no such tumours were found [1]. The 
well-established relationship between the occurrence of hormone receptors and 
the hormonal dependence of mammary tumours [2] has stimulated the belief 
that estimation of the androgen receptor content of the human prostate could 
contribute to. a better understanding of the development of benign prostatic 
hyperplasia (BPH) and the hormonal dependence of prostatic carcinoma. 
Several laboratories have estimated cytoplasmic androgen receptors in prostatic 
tissue, but the receptor values showed a wide variation, probably as result of 
the heterogeneity of the tissue samples and the different experimental condi-
tions used for receptor estimation [ 3,4]. The measurement of cytoplasmic 
androgen receptors in prostatic tissues is complicated by the presence of high 
proteolytic activity and of high levels of endogenous DHT [ 5,6]. Additionally 
the presence of sex hormone binding globulin and a progesterone receptor can 
give erroneous results. 
It can be expected from the high endogenous levels of DHT that most of the 
cytoplasmic receptor in the prostate is translocated to the nucleus [7]. Hence, 
it could be meaningful to measure nuclear androgen receptors rather than cyto-
plasmic receptors, although the reported nuclear receptor content of BPH 
tissues also shows a rather wide variation [3,8-11]. We have attempted to over-
come some of the technical difficulties and in this report we present the results 
of: (1) a more efficient procedure for extraction of androgen receptors from 
nuclear pellets of BPH tissue; (2) optimal conditions for exchange of unlabelled 
endogenous receptor-bound steroid with radioactive added steroids in heparin 
extracts; (3) a comparison between agar gel electrophoresis, LH-20 gel filtra-
tion, protamine sulphate precipitation and sucrose density gradient centrifuga-
tion as methods for quantitative estimation of receptors; and ( 4) the effect of 
charcoal treatment of labelled nuclear extracts prior to the receptor assay. 
On the basis of these results we have combined several of these procedures in 
a method for routine estimation of nuclear androgen receptors in P.rostatic 
tissue. Results obtained with this method were compared with those published 
previously by others. A preliminary report of our results has been published 
[12]. 
Materials and methods 
Tissue 
Prostatic tissues were obtained from patients with benign prostatic hyper-
plasia undergoing open prostatectomy. After surgery, tissues were immediately 
placed on ice, divided in samples of 1-2 g and stored frozen at -80° C for 1-3 
months. Before processing the tissue was thawed on ice. 
Steroids 
The following steroids were used: 5a-dihydrotestosterone (17j3-hydroxy-
5a-androstane-3-one) (DHT); testosterone (17!)-hydroxy-4-androsten-3-one); 
progesterone ( 4-pregnene-3 ,20-dione); oestradiol (1 ,3 ,5(1 0 )-estratriene-3,1 7J)-
diol); methyltrienolone (17J)-hydroxy-17a-methyl-estra-4,9,11-trien-3-one, 
R 1881) and (1,2,4,5,6,7-3H)-DHT (specific activity 114 Cijmmol). 
3H-DHT was purchased from the Radiochemical Centre, Amersham, U.K. 
Non-labelled R 1881 was obtained from NEN Chemicals GmbH, F.R.G. Other 
unlabelled steroids were obtained from Steraloids, Pawling, New York, U.S.A. 
Preparation of nuclear extracts 
After mincing the thawed BPH tissue partly with scissors, the minces were 
homogenized between two stainless steel screens (mesh size 80). During homo-
genization 0.5 g minced tissue was kept in 40 ml buffer A (50 mmol/1 Tris-HCl, 
2.5 mmol/1 KCl, 5 mmol/1 MgCl2 , 0.55 mol/1 sucrose, pH 7.5 ). After homo-
genization the suspension was divided into two equal parts and each part was 
layered onto 25 ml buffer A' (sucrose concentration in buffer A increased to 
0.88 mol/1) and centrifugation was performed with a HB-4 rotor for 10 min/ 
2000 X g in a Sorvall RC2B centrifuge. After centrifugation the supernatant 
was discarded and the nuclear pellets were resuspended each in 750 .ul buffer B 
(10 mmol/l Tris-HCl, 1.5 mmol/1 EDTA, 1.5 mmol/1 dithiothreitol, 0.05 mol/1 
NaCl, pH 7 .5) and were pooled. In 100 .ul of this suspension the number of 
nuclei were counted as described by Lieskovsky and Bruchovsky [10]. The 
remainder of the nuclear suspension was centrifuged for 10 min/800 X g and 
the nuclear pellet was mixed with 2 mmol/l phosphate buffer (pH 8.0), con-
taining 1 g/1 heparin unless stated otherwise, until a final suspension was 
reached of 1-2 X 10 7 nuclei/mi. The resulting suspension was left for 1 h fol-
lowed by centrifugation for 30 min/100 000 X gin a Beckman L5-65 centrifuge 
with a SW-60 rotor. The supernatant was used as "nuclear extract". All proce-
dures were performed at 0-4°C. 
Labelling of nuclear extracts 
The nuclear extracts were incubated for different periods of time and at dif-
ferent temperatures with 10-100 nmol/1 3H-DHT. In parallel experiments 
nuclear extracts were incubated with labelled steroid and a 200-fold excess of 
non-radioactive DHT. Competition experiments were performed with 10 nmol/l 
3H-DHT in the absence and presence of 100 and 1000 nmol/1 non-labelled com-
petitors. 
Estimation of receptor levels 
Charcoal pretreatment of nuclear extracts 
To remove excess non-bound steroid and to exclude low affinity binding 
sites, labelled nuclear extracts were treated with 0.5% charcoal (Dextran 300 
coated), prior to the receptor assay. The charcoal treatment was performed for 
10 min at 0°C followed by centrifugation for 10 min/1000 X g. The super-
natant fraction was analyzed either by agar gel electrophoresis, protamine sul-
phate precipitation, LH-20 gel filtration or sucrose density gradient centrifuga-
tion. 
Agar gel electrophoresis 
Agar gel electrophoresis was performed for 90 min at 130 rnA as described 
by Wagner [13]. 
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Protamine sulphate precipitation 
Protamine sulphate precipitation was performed by the method of Chamness 
et al. [14] with acid-washed (11.5 X 75 mm) disposable glass tubes. The tubes 
were incubated at 30°C for 15 min with 0.5 ml buffer B containing 0.1% 
bovine serum albumin and were then rinsed with 1 ml ice-cold buffer C (10 
mmol/l Tris-HCI, 1.5 mmol/1 EDTA, 1.5 mmol/1 dithiothreitol, 10% glycerol, 
pH 7 .5). Protamine sulphate (Organon, Oss, The Netherlands) was diluted to a 
final concentration of 1 g/1 in buffer C and 450 ,ul was added to each tube. A 
protamine sulphate concentration above 1 g/l did not change the amount of 
precipitable specifically bound radioactive steroid. After treatment with char-
coal 50 ,ul samples were added to the protamine sulphate solution, mixed with 
a Vortex and left for 5-10 min at 0°C before centrifugation at 2400 Xg for 
15 min. The firmly coated precipitates were washed five times with 1 ml buffer 
C without further centrifugation. The pellets were dissolved with 0.5 ml 
soluene (Packard Instrument) for 10 min at 60°C and counted for radioactivity. 
All values reported are means of duplicate experiments. 
LH-20 gel filtration 
LH-20 (Pharmacia) gel filtration was performed by the method of Ginsburg 
et al. [15]. After treatment with charcoal, 50 ,ul nuclear extract samples were 
analyzed with buffer C as elution buffer. The void volume fractions were 
pooled and counted for radioactivity. All values reported are means of dupli-
cate experiments. 
Sucrose density gradient centrifugation 
After treatment with charcoal 200 ,ul of the nuclear extracts were layered on 
5-20% linear sucrose gradients prepared with Buffer C containing 0.6 mol/1 
KCL Centrifugation was performed in a SW-60 rotor for 24 h at 370 000 X gav 
in a Beckman L5-65 centrifuge at 1°C. Finally 200 ,ul fractions were collected 
by piercing the bottom of the tube and counted for radioactivity. 
Liquid scintillation counting 
For counting of radioactivity, samples were mixed with 10 ml of Insta-Gel 
(Packard Instruments) as scintillation cocktail. The pellets obtained after pro-
tamine sulphate precipitation were dissolved in soluene and were subsequently 
mixed with Insta-Gel containing 1% acetic acid and 0.1% butylated hydroxy 
toluene. 
Protein estimation 
The amount of protein in nuclear extracts was estimated as described by 
Peterson [16], which involves a protein precipitation step prior to the assay to 
eliminate interfering ingredients present in the buffers. 
Results 
Optimalization of nuclear receptor assay 
Estimation of receptor complexes in nuclear pellets 
In a first series of experiments the nuclear pellet from BPH tissue was 
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Fig. 1. Agar gel electrophoresis of labelled nuclear extracts of BPH tissue. Extraction of the nuclear pellet 
was performed for 1 h at 0° C either with 0.4 mol/1 KCl (left panel) or with 1 g/1 heparin (right panel). 
Nuclear extracts were incubated for 18 h/10°C with 10 nmol/l 3H-DHT (0-----0) or with 10 nmol/l 
3H-DHT in the· presence of 2 .umol/1 non-radioactive DHT (e-----e); "free", position of unbound 
steroid; ''arrow", position of sample at start of electrophoresis. 
extracted with a buffer containing 0.4 mol/l KCl and the nuclear extract was 
incubated with 3H-DHT and subsequently subjected to agar gel electrophoresis. 
Fig. 1 (left panel) shows that the specifically bound radioactive tracer was 
located at the application site (arrow) and free steroid had migrated to the 
cathodic region of the gel. This indicates an aggregated form of the receptor 
protein, which might have been caused by either storage at -80°C or by the 
homogenization or extraction procedures. 
In an earlier report from this laboratory it has been shown that rat prostate 
nuclear androgen receptor could partly be deaggregated by the use of heparin 
[17]. After extraction of th~ nuclear pellet from BPH tissue with a buffer con-
4 
3 
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0+------------------r-----------------,-
0 0.5 
heparin (gjl) 
1.0 
Fig. 2. Effect of heparin concentration on the amount of androgen receptors in nuclear extracts of BPH 
tissue. Nuclear extracts were incubated for 18 hat 6°C with 10·nm,ol/l 3 H-DHT in the absence and pres-
ence of 2 .umol/1 non-radioactive DHT. Specifically bound 3H-DHT was estimated after agar gel electro-
phoresis and plotted; 01-----m, without sonication; e-<1>, with sonication for 3 X 5 s (with inter-
mediate cooling) with an MSE 100 W Ultrasonic Disintegrator stand height 4. Sonication was performed 
at the start of the 1 h extraction period. 
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taining heparin followed by agar gel electrophoresis, the specifically bound 
3H-DHT was reflected in a peak towards the anodic region of the agar gel, 
which indicates deaggregation of the androgen receptor molecules (Fig. 1, right 
panel). After agar gel electrophoresis of nuclear extracts containing heparin, in 
some cases a residual peak of specifically bound 3H-DHT was still observed at 
the application site, which suggests that deaggregation was not complete. In the 
calculations of the total amount of specifically bound steroid, we included this 
amount of specifically bound steroid at the application site. Additionally, 
extraction of nuclear pellets with a buffer containing heparin (1 gjl) appeared 
to be twice as efficient in extracting androgen receptors as extraction with a 
buffe-r containing 0.4 mol/1 KCl (82 ± 7 and 49 ± 2 pmoljg protein respectively, 
which corresponds with 2333 ± 192 and 1005 ± 31 molecules/nucleus; mean± 
S.D., n = 5). 
The effect of sonication and the influence of the heparin concentration on 
the amount of extractable androgen receptors was investigated. From the 
results given in Fig. 2 it appeared that addition of 0.5 or 1.0 gjl heparin to the 
extraction buffer abolished the effect of sonication on the extractable amount 
of androgen receptors, which was observed in the absence of heparin. Sonica-
tion of nuclear pellets, however, caused an increase in non-specific binding. The 
amounts of specifically bound steroid (as plott.ed in Fig. 2) were not different. 
In all further experiments a heparin concentration of 1 g/1 was used and sonica-
tion of the nuclear pellet was omitted. Extraction was complete after 1 h at 
0° C and as a star.dard procedure 1-2 X 107 nuclei were extracted with 1 ml 
extraction buffer. 
Labelling of nuclear extracts via the exchange procedure 
To evaluate optimal conditions for receptor estimation, exchange was 
studied at different temperatures and for different times and optimal concen-
tration of added radioactive steroid was determined. The exchange of added 
radioactive steroid (10 nmol/1 3H-DHT) was studied at different temperatures 
for 18 h. Optimal exchange of added radioactive ligand for endogenous bound 
steroid was achieved between 8°C and 20°C with a maximum at approximately 
10°C. To determine the optimal concentration for added 3H-DHT, a Scatchard 
plot was constructed (Fig. 3), showing a single type of binding site with an 
apparent Kn of 1.7 X 10-9 mol/1. It was calculated from the Scatchard plot that 
maximal exchange occurred when the ratio free/bound ligand is approximately 
80 : 1. For tissue samples with high levels of androgen receptors, a concentra-
tion of 50 nmol/1 3H-DHT present during the exchange appeared to be suffi-
cient. To ensure that no underestimation of receptors occurred as a result of 
the endogenous DHT present, 1-2 X 107 nuclei were extracted with 1 ml 
extraction buffer. In the diluted extracts used, the concentration of endogenous 
(non-labelled) DHT was maximally 0.5 nmol/1 (n = 15). The added amount of 
radioactive ligand should be at least 100 times higher than endogenous steroid. 
Therefore the use of 50 nmol/1 3H-DHT in the presence of such small amounts 
of endogenous steroid will not lead to underestimations of receptors. Studies 
with variable exchange times at 10°C with 50 nmol/1 3H-DHT as exchange 
ligand showed that after 20 h a maximal amount of androgen receptors was 
labelled, which remained constant up to at least 50 h (Fig. 4). 
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Fig. 3. DHT binding in nuclear extracts of BPH tissue. Nuclear extract samples were incubated for 20 hat 
10° C with increasing amounts of 3H-DHT. Bound (B) and free (F) steroid were separated by protamine 
sulphate precipitation. Recoveries for free steroid were taken directly from the incubation samples. Cor-
rection for non-specific binding was made according to the method described by Rosenthal [18]. 
(<0------41 before correction; 0---0 after correction). [B], presumably bound. 
Comparison of different androgen receptor assays 
Results of receptor assays obtained with protamine sulphate precipitation as 
compared with agar gel electrophoresis or with LH-20 gel filtration are pre-
sented in Fig. 5. The amounts of androgen receptor molecules per nucleus are 
plotted and showed good mutual correlation (correlation coefficients of r = 
0.98, n = 8 and r = 0.99, n = 7) respectively. The application-of agar gel electro-
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Fig. 4. Effect of incubation time on labelling of androgen receptors in nuclear extracts of BPH tissue. 
Nuclear extracts were incubated at l0°C with 50 nmol/1 3H-DHT in absence(., ___ .,) and presence of 
10 j.lmol/1 non-radioactive DHT (~----C). The amounts of androgen receptors were quantified with 
protamine sulphate precipitation (m---m specifically bound 3 H-DHT). 
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Fig. 5. Comparison of the amount of androgen receptors in nuclear extract of BPH tissue, estimated by 
either protamine sulphate precipitation or agar gel electrophoresis and LH-20 gel filtration. Nuclear 
extracts were incubated for 18-20 h at 10° C with 10 nmol/l 3 H-DHT in the absence and presence of 
2 j.Lmol/1 non-radioactive DHT and the number of molecules/nucleus (Xl03 ) are plotted: [ARlagar = 0.61 
[ARlP.S. + 314 (n = 8); [ARlLH-20 = 0.88 [ARlP.S. -182 (n = 7)). 
phoresis and LH-20 gel filtration as techniques to separate bound from free 
ligand resulted in lower estimated androgen receptor levels than protamine sul-
phate precipitation (26 and 16% respectively). 
An example of a profile of radioactive DHT obtained after sucrose gradient 
centrifugation is shown in Fig. 6. The specifically bound 3H-DHT mainly 
migrated in the 4 S region. The higher amount of radioactivity present at the 
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Fig. 6. Sucrose density gradient centrifugation of labelled nuclear extracts of BPH tissue. Nuclear extracts 
were incubated with 10 nrnol/l 3H-DHT in the absence (•-) and presence of 2 j.Lmol/l non-radio-
active DHT (0---o). ("Arrow" indicates position of BSA (4.6 S).) 
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Fig. 7. Effect of charcoal pre-treatment on the estimated amount of androgen receptors in labelled 
nuclear extracts of BPH tissue. Nuclear extracts were incubated for 20 hat 10°C with 10 nmolfl3H-DHT 
in absence and presence of 2 J.lmol/1 non-radioactive DHT. Samples were analyzed by either LH-20 gel fil-
tration or protamine sulphate precipitation and the number of specifically bound 3H-DHT in molecules"/ 
nucleus (X103 ) are plotted: ([ARl+cc ; 0.69 [ARl-ee + 176 (n ; 12)). 
top of the gradient (upper curve Fig. 6) is probably due to partial dissociation 
of the androgen receptor complex during the run. 
The effect of charcoal pre-treatment of the nuclear extracts prior to the recep-
tor assay 
The androgen receptor estimations described so far in this report were per-
formed after treatment of the incubated nuclear extracts with a charcoal sus-
pension prior to the receptor assay. This pre-treatment resulted in the removal 
of excess non-bound steroid and exclusion of low affinity binding sites. 
Fig. 7 shows the amount of specifically bound 3H-DHT in molecules/nucleus, 
estimated after treatment of the labelled nuclear extract with charcoal prior to 
the receptor assay, versus the amount of estimated receptors when charcoal 
treatment was omitted. The number of receptors estimated was 26% lower 
when charcoal pre-treatment was performed. 
TABLE I 
SPEQIFICITY OF 3H-DHT BINDING TO NUCLEAR EXTRACTS OF BPH TISSUE 
Nuclear extracts were incubated for 20 hat 10°C with 10 nmol/1 3H-DHT in absence and presence of 100 
and 1000 nmol/1 non-radioactive competitors. Receptors were estimated by pr·otamine sulphate precipita-
tion. 
Competitor 
None 
Dihydrotestosterone 
Methyltrienolone 
Testosterone 
Progesterone 
Oestradiol 
* Duplicate experiments. 
**Mean± S.D. (n = 4). 
Residual binding (%) 
100 nmol/1 
100 
11- 20 * 
22- 30 * 
41- 65 * 
112-126 * 
101-103 * 
1000 nmol/1 
100 
0 
20 ± 12 ** 
20 ± 15 ** 
100 ± 15 ** 
70 ± 6 ** 
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Specificity of DHT binding to nuclear extracts of BPH tissue 
The specificity ofDHT binding in nuclear extracts of BPH tissue was studied. 
When 3 H-DHT was incubated in the presence of steroid competitors, it was 
found that radio-inert dihydrotestosterone, R 1881 and testosterone showed 
the highest competition, whereas oestradiol and progesterone did not show any 
competition in 10-fold excess and only small competition in 100-fold excess 
(Table I). 
Discussion 
The present results show that the use of a buffer containing heparin for 
extraction of receptors from nuclear pellets of BPH tissue offers several advan-
tages over extraction with a buffer containing KCL Compared to extraction 
with 0.4 mol/1 KCl the yield of solubilized receptors after heparin extraction 
was improved. This may reflect that with heparin also the salt-resistant recep-
tor sites [10] are solubilized. An additional advantage of extraction with a 
buffer containing heparin appeared to be the partial deaggregation of the recep-
tor proteins (Fig. 1). This is in agreement with previous observations that rat 
prostate nuclear androgen receptors after storage at -80°C could be deaggre-
gated by heparin [17]. 
The purpose of the present study was to define optimal conditions for the 
exchange of occupied nuclear receptors and to evaluate some of the discre-
pancies described in the literature concerning the amount of nuclear androgen 
receptors in BPH tissue [3,8-11]. The differences reported are probably not 
only the result of heterogeneity of the tissue samples, but are also caused by 
storage of tissue and the experimental conditions used for procedures such as 
homogenization of the tissue-, the exchange of bound ligands, and the separa-
tion of bound from free ligand. 
In the comparison of values for nuclear androgen receptor levels estimated 
by either protamine sulphate precipitation, LH-20 gel filtration or agar gel 
electrophoresis, the highest values of specifically bound steroid obtained by 
single point assays with 10 nmol/1 3H-DHT as exchange ligand were obtained 
with the protamine sulphate precipitation technique. Decreasing values of 
bound steroid were obtained in the sequence: protamine sulphate p:::osipita-
tion > LH-20 gel filtration> agar gel electrophoresis (Fig. 5 ). The number of 
androgen receptors estimated appeared to be inversely proportional to the time 
required to perform the assay, probably due to lability and fast dissociation of 
androgen-receptor complexes. This was also supported by the observation that 
after sucrose gradient centrifugation (24 h) a significant difference was found 
in radioactivity at the top of the gradient (Fig. 6). 
Apart from the experiments presented in Fig. 7, in all the androgen receptor 
assays described in this paper, pre-treatment of the labelled nuclear extracts 
with a charcoal suspension was used for removal of excess non-bound steroid 
and for reduction of non-specific binding. When exchange was performed with 
higher concentrations of 3H-DHT (50 nmol/1) and charcoal pre-treatment was 
omitted, the values obtained after agar gel electrophoresis and protamine sul-
phate precipitation were very difficult to interpret. The reason for this diffi-
culty is the very high non-specific binding which occurs after long exchange 
periods. Also in the literature very high non-specific binding in nuclear extracts 
has been reported after exchange for long periods (8,11]. 
We have concluded from the present results that estimation of nuclear andro-
gen receptors in BPH tissue after storage at -80°C by extraction of the nuclear 
pellet with a buffer containing heparin offers certain advantages over other 
methods. Optimal conditions for exchanging added labelled steroids for endo-
genous bound steroid do not differ much from those reported in the literature 
[3,8-11], but the protamine sulphate precipitation technique gave the highest 
numbers of androgen receptors in our estimations. An additional advantage of 
this technique is the experimental convenience of analyzing several samples at 
the same time. For routine purposes the best procedure would be the prota-
mine sulphate precipitation technique, because a lot of samples can be pro-
cessed at the same time. For accurate measurements of receptor levels and dis-
sociation constants, it is advisable to produce Scatchard plots in initial experi-
ments. In subsequent experiments a 2-point assay may give reliable results. 
In the literature discrepancies are reported with respect to the amount of 
cytoplasmic androgen receptors and clinical response in carcinomatous human 
prostatic tissue [20-22]. However, the measurement of cytoplasmic androgen 
receptors is complicated by the presence of high proteolytic activity and high 
levels of endogenous DHT [ 5,6], which is known to translocate the receptor to 
the nucleus. Additionally, using R 1881 and DHT as exchange ligands, the 
presence of a progesterone receptor [23] and sex hormone binding globulin 
[ 5] may give erroneous results. In this respect the applicability of a nuclear 
receptor assay may become increasingly important, because the estimation of 
nuclear androgen receptors in prostatic carcinoma tissue may assist in selecting 
the appropriate therapy for patients suffering from this disease. 
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An androgen receptor has been demonstrated in the cytosol and in the nuclear fraction of 
ram seminal vesicles. 
The cytosol receptor was stabilized by sodium molybdate and 2 distinct [3 H]methyltri-
enolone-binding proteins, one sedimenting at 9S and one sedimenting at 3S, could be demon-
strated by sucrose-gradient centrifugation in the presence of 50 mM molybdate. The slower 
sedimenting form could be partially purified by ADP~sepharose chromatography. The purified 
receptor still sedimented at 3S after centrifugation on sucrose gradients containing either 0.6 M 
KCl or 50 mM molybdate. The receptor was destroyed by heating at 50°C for 30 min and its 
complex with eHJmethyltrienolone dissociated slowly at low temperatures. The apparent 
equilibrium-dissociation constant (Ko) for the purified receptor was: 3.8 X 10-10 M. The rela-
tive affinities for different steroids decreased in the following sequence: 5a-dihydrotestoster-
one ;;, methyltrienolone > testosterone ;p estradiol > R5 020 > progesterone > diethylstil-
bestrol. 
The nuclear androgen receptor sedimented at 3S on sucrose gradients containing 0.6 M KCI. 
At pH 7.4 it behaved as an acidic protein with an electrophoretic mobility towards the anodic 
region of the agar gel. 
Because of the relatively large content of cytoplasmic and nuclear androgen receptors and 
the availability of large amounts of tissue the ram seminal vesicles could be a suitable source for 
large-scale purification of these receptors. 
Keywords: androgen receptor; testosterone; protein purification. 
From studies on rat prostate it is now generally accepted that androgens initiate 
their cellular action Via steroid-receptor complexes in the cytosol, which after a 
conformation change are translocated to the nucleus (Liao and Fang, 1969; Main-
waring, 1977). The hypothesis that androgen-hormone receptors associate with 
chromatin, thus influencing gene transcription, has led to intensive research on the 
characterization of these receptor molecules and their nuclear-acceptor sites 
(Rennie, 1979; Davies et al., 1980). 
The lack of pure receptors is a major obstacle for further investigation of the 
mechanism of action. The limited amount of androgen receptor present and the 
small size of androgen target tissue make the rat prostate unattractive as a source 
0303-7207 /81/0000~0000/$02.50 ©1981 Elsevier/North-Holland Scientific Publishers, Ltd. 
121 
J.A. Foekens et al. 
for androgen receptor purification. The presence of cytoplasmic androgen receptors 
has been reported also for seminal vesicles of rat and mouse (Mainwaring and 
Mangan, 1973) and ram testis (Monet-Kuntz et aL, 1979). We have investigated ram 
seminal vesicles as a possible source for large-scale receptor purification. 
In this publication we demonstrate the presence of large amounts of an andro-
gen-binding protein with characteristics of an androgen receptor in seminal vesicle 
tissue of the ram. 
MATERIALS AND METHODS 
Tissue 
Seminal vesicle tissue from adult rams was removed as soon as possible after 
killing the animals and was directly frozen at -20°C. After transportation from the 
slaughterhouse, the tissue was stored at -80°C. For measurements of nuclear recep-
tors, fresh tissue was used after transportation on ice. 
Steroids 
The following steroids were used: 5a-dihydrotestosterone (1713-hydroxy-5a-
androstan-3-one ); testosterone (17 13-hydroxy-4-androsten-3-one) (T); methyltrienol-
one (1713-hydroxy-17a-methyl-4,9,11-estratrien-3-one) (R1881); R5020 (17,21-
dimethyl-19-norpregna-4,9-diene-3,20-dione ); 1713-estradiol (1 ,3,5-(10)-estratriene-
3 ,17 13-diol); progesterone ( 4-pregnane-3 ,20-dione ); diethylstilbestrol (3 ,4-bis-
(-hydroxy-phenyl)-3-hexene ). 
[17a-Me-3 H]Rl881 (spec. act. 87 Ci/mmole), unlabelled R5020 and Rl881 
were purchased from NEN Chemicals, GmbH (West Germany). [1,2,6,7-3H]T (spec. 
act. 93 Ci/mmole) was obtained from the Radiochemical Centre, Amersham 
(England). 
Other unlabelled steroids were purchased from Steraloids, Pawling, NY (U.S.A.). 
Cytoplasmic and nuclear receptors 
For preparation of cytosols, seminal vesicles stored at -80°C were used after 
thawing on ice. Minced tissue was homogenized in 2-3 volumes of TEDG buffer 
(10 mM Tris-HCl, 1.5 mM EDTA, 1.5 mM dithiothreitol with 10% glycerol; buffer 
A, pH 7 .4) with a Waring Blendor for 1 X 60s at 4°C (in some experiments, as indi-
cated, sodium molybdate was added to the homogenization buffer). The homo-
genate was centrifuged for 45 min at 96 000 X gavin a Beckman SW-27 rotor and 
the supernatant was designated as "cytosol". 
For labelling of nuclear receptors, minces of fresh seminal vesicle tissue were 
incubated for 1 hat 37°C in Eagle's minimal essential medium with 20 nM [3 H]tes-
tosterone. The tissue was homogenized in 3 volumes of buffer B (buffer A, without 
glycerol) with 3 X 10 s strokes of an Ultraturrax tissue-homogenizer and the 
700 X g nuclear pellet was prepared. The pellet was washed with buffer B contain-
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ing 0.2% Triton X-100 and subsequently 2 times with buffer B. A nuclear extract 
was prepared by extracting the washed nuclear pellet with 0.6 M KCl in buffer B 
(pH 8 .4) for 1 hat 0°C and centrifugation for 15 min at 10 000 X g. 
Pretreatment with charcoal 
Excess unbound steroid was removed in some experiments by adding 2.5 mg 
dextran-coated charcoal to 1 ml of sample. After mixing, the suspensions were incu-
bated for 15 min at 0°C and charcoal was removed by centrifugation for 15 min at 
lOOOOXg. 
Measurement of steroid binding 
Separation of free and bound steroid was performed using either Sephadex 
LH-20 gel filtration, sucrose-gradient centrifugation or agar gel electrophoresis. 
Sephadex LH-20 gel ftltration was performed according to Ginsburg et al. 
(1974). After incubation 100-pl samples were analyzed with buffer A as elution 
buffer. The void volume fractions were pooled and counted for radioactivity. 
For sucrose-gradient analysis of cytosol and partially purified receptor prepara-
tions, a 250-pl sample was centrifuged at 1 °C in linear 10-30% sucrose gradients in 
buffer A (with or without additions) for 3.5 h at 370000 Xgav in a Beckman 
VTi-65 rotor. For sucrose-gradient analysis of nuclear extracts, a 200-pl portion of 
a 0.6 M KCl extract was centrifuged at 1 °C in linear 5-20% sucrose gradients in 
buffer B for 18 hat 310 000 Xgav in a Beckman SW-60 rotor. 
Agar-gel electrophoresis was performed as described by Wagner (1972). 
Protein determination 
Protein was estimated according to Bradford et al. (1976). 
Liquid-scintillation counting 
For counting of radioactivity samples were mixed with 10 ml of Insta-Gel 
(Packard Instrument) as scintillation cocktail. 
RESULTS 
Binding of [ 3H}methyltrienolone to cytosols of ram seminal vesicle tissue 
For the study described in this report, seminal vesicles were obtained from a vari-
able population of non-castrated rams. For this reason steroid-binding studies were 
performed under conditions where exchange of added radioactive steroid with 
endogenously bound steroid could be expected. Labelling experiments were per-
formed with [3H]methyltrienolone, a synthetic androgen with high affmity for 
androgen receptors and not liable to attack by 3-hydroxysteroid dehydrogenases 
(Bonne and Raynaud, 1975). In the absence of molybdate maximal binding of 
[ 3 H]methyltrienolone to cytosol fractions was obtained between 10 and 23 h with 
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Fig. 1. Time course of [3 H]methyltrienolone binding to ram seminal vesicle cytosol. Cytosols 
prepared in absence (A) or presence of 50 mM molybdate (B) were incubated with 10 nM [3H]-
methyltrienolone in the absence or presence of 1 !LM non-radioactive methyltrienolone at 1Q°C. 
After various time intervals a 1 00-!Ll aliquot was withdrawn from the incubation mixture to 
determine total (") and non-specific binding ( o) with Sephadex LH-20 gel filtration. 
Fig. 2. [3H)Methyltrienolone binding to ram seminal vesicle cytosol. Cytosol was prepared in 
the presence of 50 mM molybdate and incubated for 24 hat 10°C with increasing amounts of 
[ 3 H) methyltrienolone ([ 3H] Rl881) in the absence or presence of a 1 00-fold excess of non-radio-
active methyltrienolone. Samples were analyzed with Sephadex LH-20 gel filtration to deter-
mine total (") and non-specific binding ( o ). 
10 nM [3H]methyltrienolone at 10°C (Fig. lA). In the presence of 10 mM molyb-
date maximal binding was achieved after 23 h and remained constant for at least 
a further 23 h (not shown). In the presence of 50 mM molybdate maximal bind-
ing was not yet reached after 23 h (Fig. lB). In additional experiments with cyto-
sols incubated in the presence of 50 mM molybdate and with increasing amounts 
of (3H]methyltrienolone, saturation of binding sites appeared to occur at approx. 
10 nM [3H]methyltrienolone (Fig. 2). The difference in labelling found between 
incubations with 10 nM [3H]methyltrienolone in absence or presence of a 100-
fold excess of non-labelled methyltrienolone was defined as specific binding. 
Specific binding was observed already after incubation for only 45 min at 10°C 
(Fig. lA, B), and this suggests the presence of free receptors in the analyzed 
samples. 
2',5'-ADP-sepharose chromatography 
Cytosols labelled with [3H]methyltrienolone were partially purified with ADP-
sepharose chromatography (Fig. 3). The bulk of proteins bound to the gel was 
eluted at lower salt concentrations than the bound [3 H]methyltrienolone (Fig. 3). 
The radioactivity eluted from ADP-sepharose was bound to protein, because the 
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Fig. 3. Partial purification of cytoplasmic androgen receptors from ram seminal vesicles with 
2' ,5 '-ADP-sepharose. Cytosol (157 ml) prepared in buffer A containing 25 mM molybdate was 
diluted with buffer A to a final concentration of 10 mM molybdate. After incubation with con-
tinuous shaking for 20 h at 6°C with 2.2 nM [3 H]methyltrienolone in the presence of 20 ml 
swollen ADP-sepharose, the gel suspension was filtered over a glass filter. The remaining gel 
was packed in a Pharmacia column (size, 1.6 X 20 em) with buffer A. After washing with buffer 
A (18 X 20 ml) the gel was eluted with 0-1.2 M KCl in buffer A gradient (20 fractions of 
10 ml). The amounts of radioactivity measured in 100 ;Ll of the different samples are plotted 
(1--1). 
radioactivity was eluted in the void volume fraction with Sephadex LH-20 gel fll.tra-
but no protein-bound radioactivity was found after heating the eluates for 
30 min at 50°C. This indicates that [3H]methyltrienolone was bound to a saturable 
heat-labile protein, which is a generally accepted characteristic of a steroid receptor. 
Sucrose-gradient analysis of partially purified cytoplasmic androgen receptors 
Before and after heating for 30 min at 50°C aliquots of a purified fraction 
(~3700 fmoles were analyzed with sucrose-
centrifugation. After centrifugation for 18 h at 1 o C no distinct peak of 
1\0l!VRIH\0 could be demonstrated and only a tail of radioactivity 
near the of the gradient was found. This suggests that the steroid was dissoci-
ated from the proteins during centrifugation for 18 h. To overcome t:b.is dissocia-
tion problem, the time required for the sucrose-gradient centrifugation procedure 
was shortened to 210 min by centrifugation in a vertical rotor. Fig. 4 shows 
sucrose-gradient profiles of partially purified cytoplasmic androgen receptors 
(before and after heating for 30 min at 50°C) after centrifugation with a vertical 
rotor. On sucrose gradients containing 0.6 M KCl (Fig. 4A) or 50 mM molybdate 
(Fig. 4B), an androgen receptor sedimenting at 3S was identified. The lower curve 
in Fig. 4A (heat-denaturated sample) represents free steroid, which was probably 
released during denaturation of the receptor proteins. When the same fraction was 
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Fig. 4. Sucrose-gradient centrifugation of partially purified androgen receptors from ram semi-
nal vesicles cytoplasm. Eluates from the experiment as described in Fig. 5 were prepared as 
follows. After incubation of the cytosol with [3 H]methyltrienolone and ADP-sepharose, the 
gel was washed with buffer A (12 X 3 ml) and eluted with buffer A containing 0.6 M KCl 
(15 X 3 ml). Fractions 5, 6, 7 and 8 were pooled (1 0 5 00 dpm/1 00 .ul) and 25 0-.ul samples were 
layered on 10-30% sucrose gradients before (10) and after heating for 30 min at 50°C (o). Cen-
trifugation was performed in a Beckman VTi-65 rotor as described in the legends to Fig. 5. (A) 
10-30% sucrose in buffer A containing 0.6 M KCl; (B) 10-30% sucrose in buffer A containing 
50 mM molybdate. Arrows indicate positions of sedimentation marker. I, -y-globulin (7 .2S); II, 
bovine serum albumin (4.6S); HI, ovalbumin (3.6S). 
analyzed with Sephadex LH-20 gel filtration no radioactivity was found in the void 
volume fractions. 
Sucrose-gradient analysis of r Hjmethyltrienolone-labelled cytosol 
Cytosol prepared in buffer containing 50 mM molybdate was labelled with 
[ 3H]methyltrienolone in the absence ("hot") and presence of a 100-fold excess of 
non-radioactive methyltrienolone ("cold"). Fig. SA shows 2 distinct CSH]methyl-
trienolone-binding proteins, one sedimenting at 9S and one sedimenting at 3S on 
sucrose gradients containing 50 mM molybdate. 
Fig. 5. Sucrose-gradient centrifugation of ram seminal vesicle cytoplasmic androgen receptors. 
Panel A and C ("parallel" incubation): Cytosol prepared in buffer A with 50 mM molybdate 
was incubated with 10 nM [3 H]methyltrienolone in the absence ("hot") or presence of a 
100-fold excess of non-radioactive methyltrienolone ("cold") for 20 hat 6° C under continuous 
agitation. After incubation and treatment with charcoal to remove excess non-bound steroid, 
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250-).tl samples were layered on continuous 10-30% sucrose gradients prepared in buffer A 
either containing 50 mM molybdate (A) or 0,.6 M KCl (C). After centrifugation for 210 min at' 
l°C in a Beckman VTi-65 rotor at 370 000 X gavin a BeckmanL-65-5 centrifuge, 200-).Ll frac-
tions were collected from the bottom of the tube and counted for radioactivity (e, total; o, 
aspecific binding). Panel B and D ("supernatant" fraction): A fraction of the same "hot" cyto-
sol (40 ml) was labelled in the presence of swollen ADP-sepharose under continuous agitation. 
After incubation for 20 hat 6°C the fraction not bound to ADP-sepharose was analyzed (after 
charcoal treatment) by sucrose-gradient centrifugation in the same run as described above (B, 
50 mM molybdate in buffer A; D, 0.6 M KCl in buffer A). (e, total binding in supernatant frac-
tion; o, supernatant fraction after heating for 30 min at 50°C in the presence of 1 JLM non-
radioactive methyltrienolone). I, '}'-globulin (7.2S); II, bovine serum albumin (4.6S); III, oval-
bumin (3.6S). 
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Another aliquot of the same "hot" cytosol was mixed with ADP-sepharose at 
the start of the incubation, allowing the proteins to bind to the gel during the 
labelling procedure with [3 H]methyltrienolone. After incubation and separation 
of the non-bound ("supernatant") fraction from the gel by low-speed centrifuga-
tion, the "supernatant" was analyzed on sucrose gradients containing 50 mM 
molybdate (Fig. SB). 
The slower sedimenting [3 H]methyltrienolone-binding form (3S) was signifi-
cantly reduced by ADP-sepharose binding, whereas approx. the same amount of 
the faster sedimenting form (9S) was still present (Fig. SA compared to Fig. 5B). 
This implies that only the 3S form of the androgen receptor was bound to the gel. 
This slower sedimenting form is probably the activated form of the androgen recep-
tor, because activation of steroid receptors is commonly required before binding to 
nuclei or DNA-like matrices occurs (Spelsberg et al., 1971; Schrader et al., 1972; 
Weichman and Notides, 1979; Liao et al., 1980; Noma et al., 1980; Sato et al., 
1980). 
For studying the sedimentation behaviour of the methyltrienolone-binding pro-
teins in high salt, the samples ("hot", "cold", Fig. 5C, and "supernatant" before 
and after heating for 30 min at 50°C, Fig. SD) were centrifuged on sucrose gra-
dients containing 0.6 M KCL A complete shift to the slower sedimenting 3S form 
was observed, which might reflect activation of the receptor (Fig. 5C compared to 
Fig. 5A; Fig. 5D compared to Fig. SB). The f~action which did bind to ADP-sepha-
rose was already analyzed as described in Fig. 4, showing only the 3S form of the 
androgen receptor either on sucrose gradients containing 0.6 M KCl or 50 mM 
molybdate. 
Denaturation and dissociation of partially purified rHJmethyltrienolone-labelled 
cytoplasmic androgen receptors 
The thermal lability and dissociation kinetics of partially purified [3H]methyl-
trienolone-labelled androgen receptors were investigated by incubating purified 
[ 3H]methyltrienolone-labelled androgen-receptor complexes in the absence and 
presence of a 1 00-fold excess of non-radioactive methyltrienolone. 
In the absence of excess steroid, incubation of the 3H-labelled androgen recep-
tors for 50 h at 5 or 10°C decreased the binding only for 13 and 18% respectively 
(Fig. 6A). At higher temperatures dissociation was more pronounced. This suggests 
that [3H]methyltrienolone was bound to a thermolabile androgen receptor with 
high affinity. The decrease in binding shown in Fig. 6A presumably is the result of 
both dissociation of the steroid-receptor complex and denaturation of the recep-
tor. 
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In the presence of a 100-fold excess of non-radioactive methyltrienolone, the 
decrease in binding was more pronounced, probably as a result of the dissociation 
of the [3H] methyltrienolone-receptor complex (Fig. 6B). 
Scatchard analysis 
For estimation of the affinity constant of partially purified androgen receptors, 
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Fig. 6. Denaturation and dissociation kinetics of partially purified eHJmethyltrienolone-
receptor complexes. 0.37 nM [3 H]methyltrienolone-receptor complex was incubated for dif-
ferent times at different temperatures (e, 5°C; o, l0°C; X, l5°C; "", 20°C; rm, 25°C). At time 
intervals as indicated on the abscissa, samples were withdrawn from the incubation mixtures and 
analyzed for bound radioactivity with Sephadex LH-20 gel filtration. A, without excess methyl-
trienolone; B, with 3. 7 X 10-8 M non-radioactive methyltrienolone. 
Fig. 7. Scatchard analysis of partially purified [3 H]methyltrienolone-labelled androgen recep-
tors from ram seminal vesicles. Part of a labelled fraction (5.5 X 10-10 M [3 H]methyltrienol-
one), obtained as described in the legend to Fig. 4, was incubated for 20 hat l0°C with increas-
ing amounts of added [3 H]methyltrienolone (up to 10 nM). After incubation the samples were 
analyzed with Sephadex LH-20 gel chromatography. 
the conditions for equilibrium between steroid-receptor complex and free steroid 
should be known. However, from the results presented in Fig. 6, it is not possible to 
define the conditions for minimal denaturation of the receptor during equilibration. 
For Scatchard analysis, incubation for 20 h at 10°C condition was chosen, as a 
compromise between minimal denaturation and maximal dissociation. The 
Scatchard plot is presented in Fig. 7, showing a single type of binding sites with an 
apparent Ko of 3.8 X 10-10 M. The initial sample contained 5.5 X 10-10 M bound 
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[ 3H]methyltrienolone, as derived from the radioactivity present in the eluate after 
ADP-sepharose chromatography, which was demonstrated to be receptor-bound 
with sucrose-gradient centrifugation and with Sephadex LH-20 gel filtration. With 
Scatchard analysis a Bmax of 5.8 X 1 o-1 0 M was found (Fig. 7). 
Specificity of rHJmethyltrienolone binding to partially purified cytoplasmic 
androgen receptors 
The specificity of [3H]methyltrienolone binding to partially purified cyto-
plasmic androgen receptors was studied by incubations in the absence or presence 
of 10 and 100 nM non-labelled competitors and subsequent analysis with Sephadex 
LH-20 gel filtration. Results are e::pressed as percentage competition and are listed 
in Table 1. Androgenic steroids showed significant competition, whereas competi-
tion with estrogens and progestins was less pronounced. 
Nuclear androgen receptors 
Nuclear androgen receptors were labelled by incubating tissue minces with [3 H]-
testosterone and were analyzed with sucrose-gradient centrifugation and agar-gel 
electrophoresis. A specific androgen-binding protein sedimented at 3S on sucrose 
gradients (Fig. 8A). Agar-gel electrophoresis at pH 8.4 showed an electrophoretic 
mobility of bound radioactivity towards the anodic region of the agar gel (Fig. 8B). 
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Fig. 8. Sucrose-gradient centrifugation and agar-gel electrophoresis of nuclear androgen recep-
tors from ram seminal vesicles. Labelled nuclear extracts were analyzed with sucrose-gradient 
centrifugation (A) or agar-gel electrophoresis (B). o, total binding; o, non-specific binding; 
B.S.A., position of sedimentation marker, bovine serum albumin (4.6S); a.s., "application site", 
sample applied at the start of electrophoresis; EB and o, anodic region, cathodic region of the 
agar gel respectively; free, position of free steroid after electrophoresis. 
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Table 1 
Specificity of [3 H] methyltrienolone binding to partially purified cytoplasmic androgen recep-
tors from ram seminal vesicles 
Partially purified labelled cytosol receptors were incubated for 20 h at 10°C after addition of 
an extra amount of 1 nM [3 H]methyltrienolone (control incubation). In parallel incubations an 
additional amount of 10 nM and 100 nM competitors was added. After incubation the samples 
were analyzed for bound radioactivity with Sephadex LH-20 gel filtration. The difference 
found in bound radioactivity after incubations without and with 100 nM non-radioactive 
methyltrienolone was arbitrarily chosen as 100% competition. 
Competitor 
Methyltrienolone 
Dihydrotestosterone 
Testosterone 
Estradiol 
Progesterone 
R5020 
Die thy !stilbestrol 
DISCUSSION 
% competition 
10 nM 
90 
93 
59 
24 
22 
15 
22 
100 nM 
100 
103 
96 
50 
37 
40 
30 
The present results demonstrate that androgen receptors are present in cytosols 
and nuclear extracts of ram seminal vesicles. Possible binding of steroid to other 
androgen-binding proteins which might be present in the cytosols was circumvented 
by the use ofmethyltrienolone (Rl881), a synthetic steroid with a high affinity for 
androgen receptors (Bonne and Raynaud, 1975). This steroid does not bind to 
serum proteins (like sex-hormone-binding globulin) or prostatic binding proteins. 
Binding of [3H]methyltrienolone to a possible progesterone receptor which also 
binds methyltrienolone with high affinity (Asselin et al., 1979) was insignificant as 
illustrated by the specificity studies described in Table 1, which show that only 
androgenic steroids competed with the [3H]methyltrienolone binding for the par-
tially purified androgen receptor. In experiments with unpurified cytosol samples, 
addition of 500-fold excess triamcinolone acetonide (to block possible progesterone 
receptors present) did not result in a decrease of specifically bound [3H]methyltri-
enolone. This implies that also the non-purified [3H]methyltrienolone-binding pro-
tein behaves as the androgen receptor. 
In initial experiments it was found that with DNA-cellulose chromatography 
part of the DNA was lost from the cellulose during incubations with cytosol 
samples, resulting in very low yields of receptor (~10%) after purification. For the 
experiments described in this paper ADP-sepharose was used, because it is a stable 
matrix, resistant to DNAases and probably acting in a similar way to DNA-cellu-
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lose in receptor binding (Mulder et al., 1980). The form of the receptor which 
actually binds to nuclei or DNA-like matrices is generally defined as the ''acti-
vated" receptor. These activated forms can be obtained by several procedures, such 
as: heating, Sephadex G-25 gel filtration, dialysis, increasing the salt concentration, 
dilution and ammonium sulphate precipitation. This activation process has been 
extensively studied for different steroid receptors (De Sombre et al., 1972; Fleisch-
mann et al., 1979; Weichman and Notides, 1979; Bailly et al., 1980; Bloom et al., 
1980; Gschwendt, 1980) and recently also for androgen receptors (Noma et al., 
1980; Sato et al., 1980). Only the 3S form of the cytoplasmic androgen receptors 
from ram seminal vesicles was retained by ADP-sepharose, whereas the faster sedi-
menting (9S, "native") form did not show any interaction with the gel. This sug-
gests that also for cytoplasmic androgen receptor from ram seminal vesicles an acti-
vation step is required for binding to ADP-sepharose. Whether this activation pro-
cess is identical with a conformational change of 9S to 3S, or involves a separate 
step, cannot be deduced from our results. Molybdate does not completely prevent 
the presence of the ADP-sepharose binding form in the cytosol (Fig. SA), which 
has been reported for several other steroid receptors (Leach et al., 1979; Grody et 
al., 1980; Maki et al., 1980; Nishigori and Toft, 1980; Noma et al., 1980). The for-
mation of the ADP-binding form in our experiments might have occurred prior to 
the addition of molybdate. This is in agreement with observations on the avian 
progesterone receptor, where molybdate no longer inhibits binding to ATP-
sepharose once the receptor is present in its DNA-binding form (Toft and Nishigori, 
1979), and with glucocorticoid, androgen and estrogen receptors, where molybdate 
had no effect on nuclear binding of previously activated steroid-receptor com-
plexes (Noma et al., 1980). 
Additionally, increasing the salt concentration completely transformed the 
receptor to its slower sedimentation form (Fig. 5C, D), which is a common feature 
for steroid receptors (Steggles et al., 1971; De Sombre et al., 1972; Fleischmann 
and Beato, 1979; Bailly et al., 1980). 
The Scatchard plot presented in Fig. 7 only gives an impression of the order of 
magnitude of the affinity constant. Starting with a partially purified androgen 
receptor, completely occupied with labelled steroid, the precise equilibrium condi-
tions (minimal denaturation and maximal dissociation) cannot be exactly deter-
mined. Under conditions for minimal denaturation and incomplete equilibrium (dis-
sociation too slow), the affmity constant found will be too high. 
For the nuclear androgen-receptor, sedimentation profiles after sucrose-gradient 
centrifugation (Mainwaring, 1977) and electrophoretic mobility during agar gel 
electrophoresis (Wagner, 1972) are similar to those of rat prostate nuclear androgen 
receptor. 
Receptor proteins are present in only minute quantities in androgen target cells. 
Approx. 40 p.g of receptor protein is present in a kilogram of rat prostate tissue 
(Mainwaring and Irving, 1973) or expressed otherwise: the ventral prostates of 
4000 rats. The ram seminal vesicles used for the studies described in this report con-
Androgen receptors from ram seminal vesicles 
tained the same amount of androgen receptors per amount of tissue, and seminal 
vesicles of approx. 200 rams would contain the same amount of receptor as the 
ventral prostates of 4000 rats. Therefore, seminal vesicle tissue of rams appears to 
be a suitable source for large-scale purification of both cytoplasmic and nuclear 
androgen receptors. 
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An androgen receptor was isolated and partially purified from 
the cytosol fraction of ram seminal vesicles. An almost two 
thousand fold purification with a recovery of 33% could be ob-
tained by chromatography on 2' ,5'-ADP-sepharose, ammoniumsulphate 
precipitation and gel filtration on Ultrogel ACA-44. The labelled 
receptor was characterized by electrephoresis and sucrose 
gradient centrifugation (sedimentation at approximately 3S) . The 
purified receptor has a DNA binding-site and is specific for 
androgenic steroids. 
INTRODUCTION 
It is now generally accepted that steroid hormone receptors, 
after binding their specific steroid and subsequent activation, 
change to a form with a high affinity for DNA and/or nuclear 
chromatin. The binding of the steroid-receptor complex to nuclear 
acceptor sites results in steroid specific responses of the cell 
(1). Purified receptor preparations are of importance for study-
ing steroid-receptor complexes as metabolic regulators of genetic 
transcription in vitro. 
Large scale purification of androgen-receptor complexes has 
not yet been successful, probably due to the extreme lability of 
this receptor and the· lack of a sui table source {or isolation of 
the androgen receptor complex. The small size of the rat prostate 
permits purification of the receptor only at a small scale (2). 
The seminal vesicles of the ram contain an androgen receptor in a 
similar concentration, but this tissue is available in large 
0006-291X/82/041279-08$01.00/0 
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amounts and appears an attractive source for isolation and purif-
ication of larger quantities of receptor (3). 
In this report we describe a procedure for purification of the 
activated (DNA-binding) form of the cytoplasmic androgen receptor 
of the seminal vesicle of the ram. 
MATERIALS AND HETHODS 
Tissue: Seminal vesicle ti'Ssue from adult rams was removed as 
soon as possible after killing the animals and was directly 
frozen and stored at -aooc. 
Preparation of cytosol: After thawing on ice the tissue (75-100g) 
was homogenized with a Waring Blendor for 3x20 s at 4oc in 1-1.5 
vol. buffer A (50~~ Tris-HCl, 1.5 mM EDTA, 1.5 mM dithiothreitol 
with 10% glycerol; pH 7.4), containing 50 ~1 sodiummolybdate and 
10 ill~ testosterone. The homogenate was centrifuged for 60 min at 
96,000xgav in a Beckman SW-27 rotor and the supernatant was de-
signed as "cytosol". In some experiments phenylmethylsulphonyl-
fluoride (PHSF, 0.6 mM) and leupeptin (0.25 mM) were added during 
homogenization. 
Purification procedures and labelling of receptors: 
£~~~~=~QE:~~E~~£~~~-~~£~~~!~££~E~U~ 
Cytosol (100-150 ml) was diluted five times with buffer A contain-
ing 50 lli~ testosterone and 30-40 ml of 2',5'-ADP-sepharose 
(2 ~~oles/ml; Pharmacia, Sweden) swollen in buffer A was added. 
After incubation for 20 h at 4oc, the ADP-sepharose was extensive-
ly washed with buffer A, to remove unbound proteins and excess 
non-labelled steroids. The receptors were labelled by incubating 
the gel in 50 ml buffer A containing 10 ~1 sodiummolybdate and 
20 nM I 3H I dihydrotestosterone (S .A. 137 Ci/m.'Tlol) for 60 h at 40C 
with continuous shaking. Subsequently the gel was packed in a 
glass column (size: 1.6x20 em) and after washing with buffer A, 
the receptors were eluted with a 0-1.0 M KCl gradient in buffer A 
(30 fractions of 5 ml). For stabilization of receptors 2 nM 13HI-
dihydrotestosterone was added to the eluates. 
~~~£~i~~~~IE~~f~_E£~~iEit~fi£~~ 
Selectively pooled eluate fractions, obtained after 2',5'-ADP-
sepharose chromatography, were incubated with ammoniumsulphate 
(50% saturation) for 1 h at ooc. The precipitate, obtained by 
centrifugation for 30 min at 20,000xg, was dissolved for 1 h at 
ooc in 1 ml of buffer A with 0.4 ~ KCl. For stabilization of re-
ceptors, 2 lli~ 13Hidihydrotestosterone was added. 
~I!£~£~I-~f~:11_~~££~~f~£~~r~u~ 
Gel filtration of the concentrated receptor preparation on Ultra-
gel 4CA-44 (LKB Instrument Grr~H, Germany) was performed in buffer 
A containing 0.1 ~1 KCl. Elution was performed in a glass column 
(size: 0.9x60 em) with an elution rate of 3.0 ml/h and 1 ml frac-
tions were collected. In some experiments the eluate of the 
Ultrogel ACA-44 column was collected directly on a small (0.2 ml) 
2' ,5'-ADP-sepharose column and eluted fro~ this col~'Tln with a 
salt gradient. 
Q~~~Hi~£~ 
Samples of the eluates, obtained from 2' ,5'-ADP-sepharose columns, 
were desalted by gel filtration on small columns with Bio-Gel 
P-6DG (Bio-Rad Laboratories, Richmond, U.S.A.). 
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RESULTS AND DISCUSSIOH 
The cytosol fraction isolated from seminal vesicles of the ram 
contains an androgen receptor (3). Due to the presence of consid-
erable amounts of androgens in these animals (approximately 690 
pg testosterone and dihydrotestosterone per gram of seminal ves-
icle tissue) a large number of these receptors will be occupied 
with endogenous steroid. To obtain receptor preparations labelled 
with radioactive steroids a long incubation at 4-10°C is required 
in order to exchange endogenously bound steroid with added radio-
active ligand. We have previously observed a stabilizing effect 
of molybdate on the receptor in crude cytosol fractions. In ad-
dition it appeared to be of advantage to bind the receptor first 
to a matrix containing an immobilized nucleotide (2' ,5'-ADP-
sepharose) and to remove contaminating cytosol proteins before 
the exchange of the non-radioactive endogenous androgens with 
radioactive dihydrotestosterone. The exchange was optimal after 
60 h at 4°C and remained constant for periods up to a week. 
The specificity of the receptor bound to 2' ,5'-ADP-sepharose 
was evaluated in a competition study with i 3Hidihydrotestosterone 
(Fig. l). Almost equal competition was obtained for dihydrotesto-
sterone, testosterone and the synthetic androgen methyltrienolone 
(methyltrienolone does not bind to androgen transport proteins 
present in plasma (4,5)). Other steroids like estradiol, progeste-
rone and triamcinoloneacetonide only competed at very high concen-
trations. 
The labelled androgen receptor complexes were eluted from 
2' ,5'-ADP-sepharose with a salt gradient. At this stage a 35-50 
fold purification with a recovery of 70% was generally obtained. 
The diluted eluate could be concentrated and further purified by 
precipitation with ammoniumsulphate at 45-50% saturation. It has 
been shown that several hormone receptors in crude cytosol frac- 139 
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Figure 1: Competition of various steroids for the androgen re-
ceptor of ram seminal vesicles. The steroid-receptor complex 
bound to 0.1 ml 2' ,5'-ADP-sepharose, prepared as described in the 
Method section, was incubated for 60 hat 4oc with 20 nM !3H!-
dihydrotestosterone in the absence and presence of 60, 200 and 
1000 nM non-labelled competitors. After incubation the 2' ,5'-ADP-
sepharose gel-pellets were washed extensively with buffer A and 
the gels were counted for radioactivity. 
e---.: 5a-dihydrotestosterone (17S-hydroxy-5a-androstane-3-one); 
x---x: testosterone (17S-hydroxy-4-androstene-3-one); v---V: 17S-
estradiol (1,3,5-(10)-estratriene-3,17S-diol); o---o: methyltrie-
nolone (l7S-hydroxy-l7a-methyl-4,9,ll-estratriene-3-one); 6---6: 
progesterone (4-pregnane-3,20-dione); 0---D: triamcinoloneaceto-
nide (9a-fluoro-llS,21-dihydroxy-16a,l4-isopropylidenedioxy-l,4-
pregnadiene-3,20-dione). 
"%" =percentage residual binding; the amount of ! 3H!dihydrotes-
tosterone bound to the receptor incubated in the absence of com-
petitors was chosen as :tOO%. 
"!3H!dihydrotestosterone+competitor/! 3H!dihydrotestosterone" = 
ratio of the sum of the steroid concentration of !3H!dihydrotes-
tosterone (20 nH) + competitor (variable), divided by the con-
centration of !3H!dihydrotestosterone (20 nM). 
tions will precipitate with 30-35% saturated arnmoniumsulphate, 
but the partially purified androgen receptor in the 2' ,5'-ADP-
sepharose eluate could only be precipitated with approximately 
10% yield with 35% satured ammoniumsulphate. After inc~easing the 
ammoniumsulphate concentration to 50% saturation, more than 80% 
of the receptors were precipitated. The receptors in the anm1o-
niumsulphate precipitate could be dissolved almost completely in 
a buffer containing 0.4 M KCl. Subsequent purification of the 
concentrated receptor sample was performed by gel filtration on 
Ultrogel ACA-44 (Fig. 2). The receptor is retarded considerably 
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Figure 2: Gel filtration on Ultrogel ACA-44 of androgen receptors 
from ram seminal vesicles after partial purification with 2' ,5'-
ADP-sepharose chromatography and ammoniumsulphate precipitation. 
Protein bound radioactive steroid, indicated on the vertical axis 
as dpm/ml, has mainly eluted between 30 and 43 ml; free steroid 
between ·44 and 51 ml and non-retarded proteins between 16 and 25 
ml. Ov and Ch positions of marker proteins: ovalbumin (MW 45,000) 
and chymotrypsinogen A (MW 25,000). 
on this column and if no specific interaction occurs with the gel, 
this would suggest a Stokes radius for the receptor comparable to 
globular molecules with a molecular weight between 20,000 and 
25,000 Dalton. The receptor eluted from the Ultrogel ACA-44 co-
lumn could be concentrated on a small column with 2' ,5'-ADP-
sepharose and could be eluted with a salt gradient, resulting in 
approximately 2000-fold purification with a recovery of 33%. 
After desalting, this partially purified receptor bound to phos-
phocellulose and DNA-agarose, reflecting the presence in the re-
ceptor molecule of a domain with high affinity for DNA-like struc-
tures. The successive purification steps are summarized in 
Table 1. 
The purified receptor could be precipitated with protamine 
sulphate in the presence of 10 m}1 pyridoxal phosphate, comparable 
to observations previously made for the androgen receptor from 
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Table 1 
volume protein receptor receptor recovery purification 
(ml) (mg) (pmol) (pmol/ ( %) factor 
mg protein) 
Cytosol 104 1570 90 0.057 100 
ADP-sepharose 80 27.5 60 2.18 68 38 
chromatography 
Ammonium sulphate 1.0 8.3 48 5.7 54 100 
precipitation 
ACA-44 gel filtration 3.0 0.27 29 109 33 1.900 
+ ADP-sepharose 
chromatography 
Table 1: Purification of androgen receptors from ram seminal 
vesicles. The total amount of receptor present in the cytosol 
was estimated as the amount of receptor bound to twice the 
amount of 2' ,5'-ADP-sepharose as used for preparative purposes. 
This amount was defined as 100%. Further increase in the 
amount of 2' ,5'-ADP-sepharose did not increase the amount of 
receptor bound. 
prostate nuclei (6) . The purified receptor was further character-
ized with agar gel electrophoresis (Fig. 3A) and sucrose gradient 
centrifugation (Fig. 3B). The migration towards the anodic region 
in the agar gel during electrophoresis (Fig. 3A) distinguishes 
the receptor clearly from dihydrotestosterone binding proteins 
like SHBG (sex hormone binding globulin), which has an electro-
phoretic mobility towards the cathodic region of the agar gel (7). 
In sucrose gradients the purified receptor sedimented at approx-
imately 3S (Fig. 3B), as has been observed for the nuclear form 
of the receptor present in ram seminal vesicles (3). Isolation 
of the receptor in the presence of the protease inhibitors PMSF 
and leupeptin did not influence the elution profiles of the dif-
ferent columns or the sedimentation behaviour. This implies that 
proteolysis is no major factor in the formation of the "activated" 
3S (nuclear-binding) form. 
In conclusion, the overall recovery of the purification proce-
dure of the androgen receptor from ram seminal vesicles was 33% 
and the purification was almost 2000-fold. Assuming one steroid 
binding site per receptor molecule, the purified preparation has 
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Figure 3: Agar gel electrophoresis and sucrose gradient centri-
fugation of androgen receptors from ram seminal vesicles after 
purification as described in Table 1. Experimental procedures as 
described previously (3). 3 A: Agar gel electrophoresis after addition of 2 nM I H\dihydro-
testosterone ( ffi : anode; e : cathode; a.s.: application site 
of sample at start of electrophoresis. Free steroid was 
present in fraction 2-6; protein bound steroid was present in 
fraction 10 and ll). 
B: Sucrose gradient centrifugation (BSA indicates position of 
bovine serum albumin (4.65) after centrifugation). 
Centrifugation was performed after addition of 1 mg/ml BSA 
to the sample. Free steroid remained on top of the gradient. 
a purity of 1%. The labile nature of the purified androgen-recep-
tor complex made it thusfar difficult to accomplish further puri-
fication. This partially purified receptor preparation will now 
be used in studies on the interaction of androgen receptors with 
the genome and for preparation of antibodies agaihst androgen 
receptors. 
The purification procedure described for androgen receptors 
isolated from tissues containing relatively large amounts of 
endogenous steroids, might also be useful for the purification of 
androgen receptors from human prostatic tissues. 
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